, Volume 169, Issue 3–4, pp 257–297 | Cite as

The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment

  • Ina WeinerEmail author



Latent inhibition (LI), namely, poorer performance on a learning task involving a previously pre-exposed non-reinforced stimulus, is disrupted in the rat by the dopamine (DA) releaser amphetamine which produces and exacerbates psychotic (positive) symptoms, and this is reversed by treatment with typical and atypical antipsychotic drugs (APDs) which on their own potentiate LI. These phenomena are paralleled by disrupted LI in normal amphetamine-treated humans, in high schizotypal humans, and in schizophrenia patients in the acute stages of the disorder, as well as by potentiated LI in normal humans treated with APDs. Consequently, disrupted LI is considered to provide an animal model of positive symptoms of schizophrenia with face, construct and predictive validity.


To review most of the rodent data on the neural substrates of LI as well as on the effects of APDs on this phenomenon with an attempt to interpret and integrate these data within the framework of the switching model of LI; to show that there are two distinct LI models, disrupted and abnormally persistent LI; to relate these findings to the clinical condition.


The nucleus accumbens (NAC) and its DA innervation form a crucial component of the neural circuitry of LI, and are involved at the conditioning stage. There is a clear functional differentiation between the NAC shell and core subregions whereby damage to the shell disrupts LI and damage to the core renders LI abnormally persistent under conditions that disrupt LI in normal rats. The effects of shell and core lesions parallel those produced by lesions to the major sources of input to the NAC: entorhinal cortex lesion, like shell lesion, disrupts LI, whereas hippocampal lesion, like core lesion, produces persistent LI with changes in context, and basolateral amygdala (BLA) lesion, like core lesion, produces persistent LI with extended conditioning. Systemically induced blockade of glutamatergic as well as DA transmission produce persistent LI via effects exerted at the conditioning stage, whereas enhancement of DA transmission disrupts LI via effects at the conditioning stage. Serotonergic manipulations can disrupt or potentiate LI via effects at the pre-exposure stage. Both typical and atypical APDs potentiate LI via effects at conditioning whereas atypical APDs in addition disrupt LI via effects at pre-exposure. Schizophrenia patients can exhibit disrupted or normal LI as a function of the state of the disorder (acute versus chronic), as well as persistent LI.


Different drug and lesion manipulations produce two poles of abnormality in LI, namely, disrupted LI under conditions which lead to LI in normal rats, and abnormally persistent LI under conditions which disrupt it in normal rats. Disrupted and persistent LI are differentially responsive to APDs, with the former reversed by both typical and atypical APDs and the latter selectively reversed by atypical APDs. It is suggested that this "two-headed LI model" mimics two extremes of deficient cognitive switching seen in schizophrenia, excessive and retarded switching between associations, mediated by dysfunction of different brain circuitries, and can serve to model positive symptoms of schizophrenia and typical antipsychotic action, as well as negative symptoms of schizophrenia and atypical antipsychotic action.


Schizophrenia Latent inhibition Dopamine Antipsychotic drugs Nucleus accumbens 



I am indebted to Daphna Joel for her critical reading of the manuscript, and thank Alain Louilot for his helpful comments on Jeanblanc et al.'s (2002a, 2002b) results.


  1. Abi-Dargham A, Laruelle M, Aghajanian GK, Charney D, Krystal J (1997) The role of serotonin in the pathophysiology and treatment of schizophrenia. J Neuropsychiatr Clin Neurosci 9:1–17Google Scholar
  2. Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M, van Dyck CH, Charney DS, Innis RB, Laruelle M (1998) Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 155:761–767PubMedGoogle Scholar
  3. Abi-Saab WM, D'Souza DC, Moghaddam B, Krystal JH (1998) The NMDA antagonist model for schizophrenia: promise and pitfalls. Pharmacopsychiatry 31:104–109PubMedGoogle Scholar
  4. Ackil J, Mellgren RL, Halgren C, Frommer SP (1969) Effects of CS pre-exposure on avoidance learning in rats with hippocampal lesions. J Comp Physiol Psychol 69:739–747PubMedGoogle Scholar
  5. Adams BW, Moghaddam B (2001) Effect of clozapine, haloperidol, or M100907 on phencyclidine-activated glutamate efflux in the prefrontal cortex. Biol Psychiatry 50:750–755CrossRefPubMedGoogle Scholar
  6. Adams W, Kendell RE, Hare EH, Munk-Jorgensen P (1993) Epidemiological evidence that maternal influenza contributes to the aetiology of schizophrenia. An analysis of Scottish, English, and Danish data. Br J Psychiatry 163:522–534PubMedGoogle Scholar
  7. Aghajanian GK, Marek GJ (2000) Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res Rev 31:302–312PubMedGoogle Scholar
  8. Aguado L, San Antonio A, Perez L, del Valle R, Gomez J (1994) Effects of the NMDA receptor antagonist ketamine on flavor memory: conditioned aversion, latent inhibition, and habituation of neophobia. Behav Neural Biol 61:271–281PubMedGoogle Scholar
  9. Akbarian S, Vinuela A, Kim JJ, Potkin SG, Bunney WE Jr, Jones EG (1993) Distorted distribution of nicotinamide-adenine dinucleotide phosphate- diaphorase neurons in temporal lobe of schizophrenics implies anomalous cortical development. Arch Gen Psychiatry 50:178–187PubMedGoogle Scholar
  10. Alves CRR, Silva MTA (2001) Facilitation of latent inhibition by the atypical antipsychotic risperidone. Pharmacol Biochem Behav 68:503–506PubMedGoogle Scholar
  11. Alves CRR, Delucia R, Silva MTA (2002) Effects of fencamfamine on latent inhibition. Prog Neuropsychipharmacol Biol Psychiatry 26:1089–1093CrossRefGoogle Scholar
  12. Angrist B, Sathananthan G, Wilk S, Gershon S (1974) Amphetamine psychosis: behavioral and biochemical aspects. J Psychiatr Res 11:13–23CrossRefPubMedGoogle Scholar
  13. Angrist B, Rotrosen J, Gershon S (1980) Responses to apomorphine, amphetamine, and neuroleptics in schizophrenic subjects. Psychopharmacology 67:31–38PubMedGoogle Scholar
  14. Angrist B, Peselow E, Rubinstein M, Corwin J, Rotrosen J (1982) Partial improvement in negative schizophrenic symptoms after amphetamine. Psychopharmacology 78:128–130PubMedGoogle Scholar
  15. Angrist B, Peselow E, Rubinstein M, Wolkin A, Rotrosen J (1985) Amphetamine response and relapse risk after depot neuroleptic discontinuation. Psychopharmacology 85:277–283PubMedGoogle Scholar
  16. Anscombe F (1987) The disorder of consciousness in schizophrenia. Schizophr Bull 13:241–260PubMedGoogle Scholar
  17. Antoniou K, Bekris S, Saranti M, Stathis P, Rimikis M, Papadopoulou-Daifoti Z (2000) The effects of antipsychotic drugs on serotonergic activity in the rat hippocampus. Eur Neuropsychopharmacol 10:315–324CrossRefPubMedGoogle Scholar
  18. Arnold SE (1999) Neurodevelopmental abnormalities in schizophrenia: insights from neuropathology. Dev Psychopathol 11:440–456Google Scholar
  19. Arnold SE, Trojanowski JQ (1996) Recent advances in defining the neuropathology of schizophrenia. Acta Neuropathol 92:217–231CrossRefPubMedGoogle Scholar
  20. Arnold SE, Hyman BT, Van Hoesen GW, Damasio AR (1991) Some cytoarchitectural abnormalities of the entorhinal cortex in schizophrenia. Arch Gen Psychiatry 48:625–632PubMedGoogle Scholar
  21. Arnt J, Skarsfeldt T (1998) Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18:63–101CrossRefPubMedGoogle Scholar
  22. Asarnow RF, Marder SR, J. M, Van Putten T, Zimmerman KE (1988) Differential effect of low and conventional doses of fluphenazine on schizophrenic outpatients with good or poor information-processing abilities. Arch Gen Psychiatry 45:822–826PubMedGoogle Scholar
  23. Asin KE, Wirtshafter D, Kent EW (1980) The effects of electrolytic median raphe lesions on two measures of latent inhibition. Behav Neural Biol 28:409–418Google Scholar
  24. Bakshi VP, Geyer MA (1995) Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine. Psychopharmacology 122:198–201PubMedGoogle Scholar
  25. Bakshi VP, Swerdlow NR, Geyer MA (1994) Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J Pharmacol Exp Ther 271:787–794PubMedGoogle Scholar
  26. Bakshi VP, Geyer MA, Taaid N, Swerdlow NR (1995) A comparison of the effects of amphetamine, strychnine and caffeine on prepulse inhibition and latent inhibition. Behav Pharmacol 6:801–809PubMedGoogle Scholar
  27. Barnes NM, Sharp T (1999) A review of central 5-HT receptors and their function. Neuropharmacology 38:1083–1152CrossRefPubMedGoogle Scholar
  28. Baruch I, Hemsley D, Gray JA (1988a) Differential performance of acute and chronic schizophrenics in a latent inhibition task. J Nerv Ment Dis 176:598–606PubMedGoogle Scholar
  29. Baruch I, Hemsley DR, Gray JA (1988b) Latent inhibition and 'psychotic proneness' in normal subjects. Person Indiv Diff 9:777–783CrossRefGoogle Scholar
  30. Bassareo V, Di Chiara G (1999) Differential responsiveness of dopamine transmission to food-stimuli in nucleus accumbens shell-core compartments. Neuroscience 89:637–641Google Scholar
  31. Baxter MG, Holland PC, Gallagher M (1997) Disruption of decrements in conditioned stimulus processing by selective removal of hippocampal cholinergic input. J Neurosci 17:5230–5236PubMedGoogle Scholar
  32. Beckmann H (1999) Developmental malformations in cerebral structures of schizophrenic patients. Eur Arch Psychiatr Clin Neurosci 249:44–47Google Scholar
  33. Beckmann H, Jakob H (1991) Prenatal disturbances of nerve cell migration in the entorhinal region: a common vulnerability factor in functional psychoses. J Neural Transm 84:155–164Google Scholar
  34. Belmaker RH, Wald D (1977) Haloperidol in normals. Br J Psychiatry 131:222–223Google Scholar
  35. Berendse HW, Groenewegen HJ, Lohman AHM (1992) Compartmental distribution of ventral striatal neurons projecting to the ventral mesencephalon in the rat. J Neurosci 12:2070–2103Google Scholar
  36. Binder EB, Kinkead B, Owens MJ, Kilts CD, Nemeroff CB (2001) Enhanced neurotensin neurotransmission is involved in the clinically relevant behavioral effects of antipsychotic drugs: evidence from animal models of sensorimotor gating. J Neurosci 21:601–608PubMedGoogle Scholar
  37. Binder EB, Gross RE, Nemeroff CB, Kilts CD (2002) Effects of neurotensin receptor antagonism on latent inhibition in Sprague-Dawley rats. Psychopharmacology 161:288–295PubMedGoogle Scholar
  38. Bleuler E (1911) Dementia praecox or the group of schizophrenias. International Universities Press, New YorkGoogle Scholar
  39. Bogerts B (1991) The neuropathology of schizophrenia: Pathophysiological and neurodevelopmental implications. In: Mednick SA, TD Cannon, CE Barr, M Lyon (eds) Fetal neural development and adult schizophrenia. Cambridge University Press, Cambridge, pp 153–173Google Scholar
  40. Bogerts B (1993) Recent advances in the neuropathology of schizophrenia. Schizophr Bull 19:432–445Google Scholar
  41. Bogerts B, Meertz E, Schonfeldt-Bausch R (1985) Basal ganglia and limbic system pathology in schizophrenia. A morphometric study of brain volume and shrinkage. Arch Gen Psychiatry 42:784–791Google Scholar
  42. Bouton ME (1993) Context, time, and memory retrieval in the interference paradigms of Pavlovian learning. Psychol Bull 114:80–99PubMedGoogle Scholar
  43. Braff, DL, Sacuzzo, DP (1982) Effect of antipsychotic medication on speed of information processing in schizophrenic patients. Am J Psychiatry 139:1127–1130PubMedGoogle Scholar
  44. Braunstein-Bercovitz H, Lubow RE (1998) Are high schizotypal normal participants distractible or limited in attentional resources? A study of latent inhibition as a function of masking task load and schizotypy. J Abnorm Psychol 107:659–670CrossRefPubMedGoogle Scholar
  45. Breier A, Berg PH (1999) The psychosis of schizophrenia: prevalence, response to atypical antipsychotics, and prediction of outcome. Biol Psychiatry 46: 361–364PubMedGoogle Scholar
  46. Breier A, Wolkowitz OM, Doran AR, Roy A, Boronow J, Hommer DW, Pickar D (1987) Neuroleptic responsivity of negative and positive symptoms in schizophrenia. Am J Psychiatry 144:1549–1555PubMedGoogle Scholar
  47. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, Weinberger DR, Weisenfeld N, Malhotra AK, Eckelman WC, Pickar D (1997) Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 94:2569–2574PubMedGoogle Scholar
  48. Broen WE (1968) Schizophrenia: research and theory. Academic Press, New YorkGoogle Scholar
  49. Broersen LM, Heinsbroek RP, de Bruin JP, Olivier B (1996) Effects of local application of dopaminergic drugs into the medial prefrontal cortex of rats on latent inhibition. Biol Psychiatry 40:1083–1090CrossRefPubMedGoogle Scholar
  50. Broersen LM, Feldon J, Weiner I (1999) Dissociative effects of apomorphine infusions into the medial prefrontal cortex of rats on latent inhibition, prepulse inhibition and amphetamine-induced locomotion. Neuroscience 94:39–46CrossRefPubMedGoogle Scholar
  51. Brown AS, Schaefer CA, Wyatt RJ, Goetz R, Begg MD, Gorman JM, Susser ES (2000) Maternal exposure to respiratory infections and adult schizophrenia spectrum disorders: a prospective birth cohort study. Schizophr Bull 26:287–295PubMedGoogle Scholar
  52. Brunello N, Masotto C, Steardo L, Markstein R, Racagni G (1995) New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropsychopharmacology 13:177–213PubMedGoogle Scholar
  53. Buhusi CV, Gray JA, Schmajuk NA (1998) Perplexing effects of hippocampal lesions on latent inhibition: a neural network solution. Behav Neurosci 112:316–351Google Scholar
  54. Cadoni C, Solinas M, Di Chiara G (2000) Psychostimulant sensitization: differential changes in accumbal shell and core dopamine. Eur J Pharmacol 388:69–76PubMedGoogle Scholar
  55. Cador M, Robbins TW, Everitt BJ, Simon H, LeMoal M, Stinus L (1991) Limbic-striatal interactions in reward-related processes: modulation by the dopaminergic system. In: Willner PJ Scheel-Kruger (eds) The mesolimbic dopamine system: from motivation to action. Wiley, Chichester, pp 225–250Google Scholar
  56. Cardinal RN, Parkinson JA, Hall J, Everitt BJ (2002) Emotion and motivation: the role of amygdala, ventral striatum and prefrontal cortex. Neurosci Biobehav Rev 26:321–352Google Scholar
  57. Carlsson M, Carlsson A (1989) The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J Neural Transm 75:221–226PubMedGoogle Scholar
  58. Carlsson M, Carlsson A (1990a) Interactions between glutamatergic and monoaminergic systems within the basal ganglia—implications for schizophrenia and Parkinson's disease. Trends Neurol Sci 13:272–276Google Scholar
  59. Carlsson M, Carlsson A (1990b) Schizophrenia: a subcortical neurotransmitter imbalance syndrome? Schizophr Bull 16:426–433Google Scholar
  60. Carlsson A, Waters N, Carlsson ML (1999) Neurotransmitter interactions in schizophrenia-therapeutic implications. Eur Arch Psychiatr Clin Neurosci 249:37–43Google Scholar
  61. Carpenter WT, Heinrichs DW, Alphs LD (1985) Treatment of negative symptoms. Schizophr Bull 11:441–452Google Scholar
  62. Carpenter WT, Heinrichs DW, Wagman AM (1988) Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 145:578–583PubMedGoogle Scholar
  63. Cassaday HF, Hodges H, Gray JA (1993a) The effects of ritanserin, RU 24969 and 8-OH-DPAT on latent inhibition in the rat. Psychopharmacology 7:63–71Google Scholar
  64. Cassaday HJ, Mitchell SN, Williams JH, Gray JA (1993b) 5,7-Dihydroxytryptamine lesions in the fornix-fimbria attenuate latent inhibition. Behav Neural Biol 59:194–207PubMedGoogle Scholar
  65. Cattabeni F, Di Luca M (1997) Developmental models of brain dysfunctions induced by targeted cellular ablations with methylazoxymethanol. Physiol Rev 77:199–215Google Scholar
  66. Cattaneo E, Reinach B, Caputi A, Cattabeni F, Di Luca M (1995) Selective in vitro blockade of neuroepithelial cells proliferation by methylazoxymethanol, a molecule capable of inducing long lasting functional impairments. J Neurosci Res 41:640–647PubMedGoogle Scholar
  67. Cepeda C, Buchwald NA, Levine MS (1993) Neuromodulatory actions of dopamine in the neostriatum are dependent upon the excitatory amino acid receptor subtypes activated. Proc Natl Acad Sci USA 90:9576–9580PubMedGoogle Scholar
  68. Cepeda C, Colwell CS, Itri JN, Chandler SH, Levine MS (1998) Dopaminergic modulation of NMDA-induced whole cell currents in neostriatal neurons in slices: contribution of calcium conductances. J Neurophysiol 79:82–94PubMedGoogle Scholar
  69. Chatterjee A, Chakos M, Koreen A, Geisler S, Sheitman B, Woerner M, Kane JM, Alvir J, Lieberman JA (1995) Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. Am J Psychiatry 152:1724–1729PubMedGoogle Scholar
  70. Chergui K, Charlety PJ, Akaoka H, Saunier CF, Brunet J-L, Buda M, Svensson TH, Chouvet G (1993) Tonic activation of NMDA receptors causes spontaneous burst discharge of rat midbrain dopamine neurons in vivo. Eur J Neurosci 5:137–144PubMedGoogle Scholar
  71. Christison GW, Atwater GE, Dunn LA, Kilts CD (1988) Haloperidol enhancement of latent inhibition: relation to therapeutic action? Biol Psychiatry 23:746–749Google Scholar
  72. Clark AJM, Feldon J, Rawlins JNP (1992) Aspiration lesions of rat ventral hippocampus disinhibit responding in conditioned suppression or extinction, but spare latent inhibition and the partial reinforcement extinction effect. Neuroscience 48:821–829Google Scholar
  73. Cools A, Jaspers R, Schwartz M, Sontag KH, Vrijmoed de Vries M, Van den Bereken J (1984) Basal ganglia and switching motor programs. In: McKenzie JS, Kemm RE, Wilcock N (eds) The basal ganglia. Plenum Press, New York, pp 513–544Google Scholar
  74. Cornblatt B, Erlenmeyer-Kimling L (1984) Early attentional predictors of adolescent behavioral disturbances in children at risk for schizophrenia. In: Watt NF, Anthony EF, Wynne LC, Rolf JE (eds) Children at risk for schizophrenia: a longitudinal perspective. Cambridge University Press, New YorkGoogle Scholar
  75. Cornblatt B, Lezenweger MF, Dworkin RH, Erlenmeyer-Kimling L (1985) Positive and negative schizophrenic symptoms, attention, and information processing. Schizophr Bull 11:397–408PubMedGoogle Scholar
  76. Cornblatt B, Winters L, Erlenmeyer-Kimling L (1989) Attentional markers of schizophrenia: evidence from the New York high-risk study. In: Schulz SC, Tamminga CA (eds) Schizophrenia: scientific progress. Oxford University Press, New York, pp 83–92Google Scholar
  77. Cornea-Hebert V, Riad M, Wu C, Singh SK, Descarries L (1999) Cellular and subcellular distribution of the serotonin 5-HT2A receptor in the central nervous system of adult rat. J Comp Neurol 410:187–209CrossRefGoogle Scholar
  78. Coutureau E, Galani R, Gosselin O, Majchrzak M, Di Scala G (1999) Entorhinal but not hippocampal or subicular lesions disrupt latent inhibition in rats. Neurobiol Learn Mem 72:143–157CrossRefPubMedGoogle Scholar
  79. Coutureau E, Gosselin O, Di Scala G (2000) Restoration of latent inhibition by olanzapine but not haloperidol in entorhinal cortex-lesioned rats. Psychopharmacology 150:226–232CrossRefPubMedGoogle Scholar
  80. Coutureau E, Blundell PJ, Killcross S (2001) Basolateral amygdala lesions disrupt latent inhibition in rats. Brain Res Bull 56:49–53CrossRefPubMedGoogle Scholar
  81. Coutureau E, Lena I, Dauge V, Di SG (2002) The entorhinal cortex-nucleus accumbens pathway and latent inhibition: a behavioral and neurochemical study in rats. Behav Neurosci 116:95–104CrossRefPubMedGoogle Scholar
  82. Cowell PE, Kostianovsky DJ, Gur RC, Turetsky BI, Gur RE (1996) Sex differences in neuroanatomical and clinical correlations in schizophrenia. Am J Psychiatry 153:799–805PubMedGoogle Scholar
  83. Crider A (1997) Perseveration in schizophrenia. Schizophr Bull 23:63–74PubMedGoogle Scholar
  84. Csernansky JG, Murphy GM, Faustman WO (1991) Limbic-mesolimbic connections and the pathogenesis of schizophrenia. Biol Psychiatry 30:383–400PubMedGoogle Scholar
  85. Daniel DG, Breslin N, Clardy J, Goldberg T, Gold J, Kleinman J, Weinberger DR (1990) The effect of l-DOPA on negative symptoms: cognitive performance and regional cerebral blood flow in schizophrenia. Biol Psychiatry 27:118AGoogle Scholar
  86. Dao-Costellana MH, Paillere-Martinot ML, Hantraye P, Attar-Levy D, Remy P, Crouzel C, Artiges E, Feline A, Syrota A, Martinot JL (1997) Presynaptic dopaminergic function in the striatum of schizophrenic patients. Schizophr Res 23:167–174CrossRefPubMedGoogle Scholar
  87. Davidson M, Keefe RS, Mohs RC, Siever LJ, Losonczy MF, Horvath TB, Davis KL (1987) l-Dopa challenge and relapse in schizophrenia. Am J Psychiatry 144:934–938PubMedGoogle Scholar
  88. De la Casa G, Lubow RE (1994) Memory for attended and nominally unattended stimuli in low and high psychotic-prone normal subjects: the effects of test-anticipation. Person Indiv Diff 17:783–789CrossRefGoogle Scholar
  89. De la Casa LG, Ruiz G, Lubow RE (1993a) Amphetamine-produced attenuation of latent inhibition is modulated by stimulus pre-exposure duration: implications for schizophrenia. Biol Psychiatry 33:707–711PubMedGoogle Scholar
  90. De la Casa LG, Ruiz G, Lubow RE (1993b) Latent inhibition and recall-recognition of irrelevant stimuli as a function of pre-exposure duration in high and low psychotic-prone normals. Br J Psychol 84:119–132PubMedGoogle Scholar
  91. De Oliveira Mora P, Fouquet N, Oberling P, Gobaille S, Graeff FG, Sandner G (1999) A neurotoxic lesion of serotonergic neurones using 5,7-dihydroxytryptamine does not disrupt latent inhibition in paradigms sensitive to low doses of amphetamine. Behav Brain Res 100:167–175CrossRefPubMedGoogle Scholar
  92. Deakin JFW (1983) Roles of serotonergic systems in escape, avoidance and other behaviors. In: Cooper SJ (ed) Theory in pharmacology, vol 2. Academic Press, London, pp 144–193Google Scholar
  93. Della Casa V, Hofer I, Weiner I, Feldon J (1999) Effects of smoking status and schizotypy on latent inhibition. J Psychopharmacol 13:45–57PubMedGoogle Scholar
  94. Denniston JC, Savastano HI, Miller RR (2001) The extended comparator hypothesis: Learning by contiguity, responding by relative strength. In: Mowrer RR, Klein SB (eds) Handbook of contemporary learning theories, vol 3. Lawrence Erlbaum Associates, Mahwah, New Jersey, pp 65–117Google Scholar
  95. Deutch AY, Cameron DS (1992) Pharmacological characterization of dopamine systems in the nucleus accumbens core and shell. Neuroscience 46:49–56PubMedGoogle Scholar
  96. Deutch AY, Lee MC, Iadarola MJ (1992) Regionally specific effects of atypical antipsychotic drugs on striatal fos expression: the nucleus accumbens shell as a locus of antipsychotic action. Mol Cell Neurosci 3:333–341Google Scholar
  97. Di Chiara G (1995) The role of dopamine in drug abuse from the perspective of its role in motivation. Drug Alcohol Depend 38:95–137PubMedGoogle Scholar
  98. Dilts RP Jr, Helton TE, McGinty JF (1993) Selective induction of Fos and FRA immunoreactivity within the mesolimbic and mesostriatal dopamine terminal fields. Synapse 13:251–263PubMedGoogle Scholar
  99. Doukas J, Cutler AH, Mordes JP (1994) Polyinosinic: Polycytidylic acid is a potent activator of endothelial cells. Am J Pathol 145:137–147PubMedGoogle Scholar
  100. Dunn LA, Scibilia RJ (1996) Reaction time and pupil response measures show reduced latent inhibition in chronic schizophrenia. Soc Neurosci 22:567Google Scholar
  101. Dunn LA, Atwater GE, Kilts CD (1993) Effects of antipsychotic drugs on latent inhibition: sensitivity and specificity of an animal behavioral model of clinical drug action. Psychopharmacology 112:315–323PubMedGoogle Scholar
  102. Ellenbroek BA, Cools AR (1990) Animal models with construct validity for schizophrenia. Behav Pharmacol 1:469–490Google Scholar
  103. Ellenbroek BA, Cools AR (1995) Maternal separation reduces latent inhibition in the conditioned taste aversion paradigm. Neurosci Res Commun 17:27–33Google Scholar
  104. Ellenbroek BA, Budde S, Cools AR (1996) Prepulse inhibition and latent inhibition: the role of dopamine in the medial prefrontal cortex. Neuroscience 75:535–542Google Scholar
  105. Ellenbroek BA, Knobbout DA, Cools AR (1997) The role of mesolimbic and nigrostriatal dopamine in latent inhibition as measured with the conditioned taste aversion paradigm. Psychopharmacology 129:112–120CrossRefPubMedGoogle Scholar
  106. Escobar M, Oberling P, Miller RR (2002) Associative deficit accounts of disrupted latent inhibition and blocking in schizophrenia. Neurosci Biobehav Rev 26:203–216Google Scholar
  107. Falkai P, Bogerts B, Rozumek M (1988) Limbic pathology in schizophrenia: the entorhinal region—a morphometric study. Biol Psychiatry 24:518–521Google Scholar
  108. Fanselow MS (2000) Contextual fear, gestalt memories, and the hippocampus. Behav Brain Res 110:73–81PubMedGoogle Scholar
  109. Feldon J, Weiner I (1988) Long-term attentional deficit in nonhandled males: possible involvement of the dopaminergic system. Psychopharmacology 95:231–236PubMedGoogle Scholar
  110. Feldon J, Weiner I (1991) The latent inhibition model of schizophrenic attention disorder: haloperidol and sulpiride enhance rats' ability to ignore irrelevant stimuli. Biol Psychiatry 29:635–646PubMedGoogle Scholar
  111. Feldon J, Weiner I (1992) From an animal model of an attentional deficit towards new insights into the pathophysiology of schizophrenia. J Psychiatr Res 26:346–367Google Scholar
  112. Feldon J, Avnimelech-Gigus N, Weiner I (1990) The effects of pre- and postweaning rearing conditions on latent inhibition and partial reinforcement extinction effect in male rats. Behav Neural Biol 53:189–204PubMedGoogle Scholar
  113. Feldon J, Shofel A, Weiner I (1991) Latent inhibition is unaffected by direct dopamine agonists. Pharmacol Biochem Behav 38:309–314CrossRefPubMedGoogle Scholar
  114. Feldon J, Shalev U, Weiner I (1995) "Super" latent inhibition (LI) with high dose of amphetamine. Soc Neurosci Abstr 21:1230Google Scholar
  115. Fendt M, Fanselow MS (1999) The neuroanatomical and neurochemical basis of conditioned fear. Neurosci Biobehav Rev 23:743–760PubMedGoogle Scholar
  116. French ED, Ceci A (1990) Non-competitive N-methyl-d-aspartate antagonists are potent activators of ventral tegmental A10 dopamine neurons. Neurosci Lett 119:159–162PubMedGoogle Scholar
  117. Frey PW, Sears RG (1978) Model of conditioning incorporating the Rescorla-Wagner associative axiom, a dynamic attention process, and a catastrophe rule. Psychol Rev 85:321–341Google Scholar
  118. Frith CD (1979) Consciousness, information processing and schizophrenia. Br J Psychiatry 134:225–235PubMedGoogle Scholar
  119. Gaisler-Salomon I, Weiner I (2003) Systemic administration of MK-801 produces an abnormally persistent latent inhibition which is reversed by clozapine but not haloperidol. Psychopharmacology DOI 10.1007/s00213-002-1311-zGoogle Scholar
  120. Gal G (2000) Disrupted and undisruptable latent inhibition following shell and core lesions: the dual role of the nucleus accumbens in latent inhibition. PhD Thesis, Tel Aviv UniversityGoogle Scholar
  121. Gallagher M, Chiba AA (1996) The amygdala and emotion. Curr Opin Neurobiol 6:221–227Google Scholar
  122. Garratt JC, Kidd EJ, Wright IK, Marsden CA (1991) Inhibition of 5-hydroxytryptamine neuronal activity by the 5-HT agonist, DOI. Eur J Pharmacol 199:350–356CrossRefGoogle Scholar
  123. Gelissen M, Cools A (1988) Effect of intracaudate haloperidol and apomorphine on switching motor patterns upon current behavior of cats. Behav Brain Res 29:17–26PubMedGoogle Scholar
  124. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 156:117–154PubMedGoogle Scholar
  125. Gilmore JH, Jarskog LF (1997) Exposure to infection and brain development: cytokines in the pathogenesis of schizophrenia. Schizophr Res 24:366–368Google Scholar
  126. Gjerde PF (1983) Attentional capacity dysfunction and arousal in schizophrenia. Psychol Bull 93:57–72CrossRefPubMedGoogle Scholar
  127. Gosselin G, Oberling P, Di Scala G (1996) Antagonism of amphetamine-induced disruption of latent inhibition by the atypical antipsychotic olanzapine in rats. Behav Pharmacol 7:820–826PubMedGoogle Scholar
  128. Gould TJ, Collins AC, Wehner JM (2001) Nicotine enhances latent inhibition and ameliorates ethanol-induced deficits in latent inhibition. Nicotine Tobacco Res 3:17–24CrossRefGoogle Scholar
  129. Grace AA (1991) Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41:1–24PubMedGoogle Scholar
  130. Grace AA (2000) Gating of information flow within the limbic system and the pathophysiology of schizophrenia. Brain Res 31:331–342Google Scholar
  131. Gracey DJ, Bell R, King DJ, Trimble KM, McDermott BG (1998) Enhancement of latent inhibition in the rat by the CCK antagonist proglumide. Pharmacol Biochem Behav 4:1053–1059CrossRefGoogle Scholar
  132. Gracey DJ, Bell R, King DJ (2000) PD-135,158, a cholecystokinin(B) antagonist, enhances latent inhibition. Pharmacol Biochem Behav 65:459–463CrossRefPubMedGoogle Scholar
  133. Gracey DJ, Bell R, King DJ (2002) Differential effects of the CCK(A) receptor ligands PD-140,548 and A-71623 on latent inhibition in the rat. Prog Neuropsychopharmacol Biol Psychiatry 26:497–504CrossRefPubMedGoogle Scholar
  134. Grahame NJ, Barnet RC, Gunther LM, Miller RR (1994) Latent inhibition as a performance deficit resulting from CS-context associations. Anim Learn Behav 22:395–409Google Scholar
  135. Gray JA (1998) Integrating schizophrenia. Schizophr Bull 24:249–266Google Scholar
  136. Gray JA, Feldon J, Rawlins JNP, Hemsley DR, Smith AD (1991) The neuropsychology of schizophrenia. Behav Brain Sci 14:1–84Google Scholar
  137. Gray JA, Joseph MH, Hemsley DR, Young AMJ, Warburton EC, Boulenguez P, Grigoryan GA, Peters SL, Rawlins JNP, Taib CT, Yee BK, Cassaday H, Weiner I, Gal G, Gusak O, Joel D, Shadach E, Shalev U, Tarrash R, Feldon J (1995) The role of mesolombic dopaminergic and retrohippocampal afferents to the nucleus accumbens in latent inhibition: implications for schizophrenia. Behav Brain Res 71:19–31PubMedGoogle Scholar
  138. Gray JA, Moran PM, Grigoryan G, Peters SL, Young AMJ, Joseph MH (1997) Latent inhibition: the nucleus accumbens connection revisited. Behav Brain Res 88:27–34PubMedGoogle Scholar
  139. Gray NS, Hemsley DR, Gray JA (1992a) Abolition of latent inhibition in acute, but not chronic, schizophrenics. Neurol Psychiatr Brain Res 1:83–89Google Scholar
  140. Gray NS, Pickering AD, Hemsley DR, Dawling S, Gray JA (1992b) Abolition of latent inhibition by a single 5 mg dose of d-amphetamine in man. Psychopharmacology 107:426–431Google Scholar
  141. Gray NS, Pilowsky LS, Gray JA, Kerwin RW (1995) Latent inhibition in drug naive schizophrenics: relationship to duration of illness and dopamine D2 binding using SPET. Schizophr Res 17:95–107PubMedGoogle Scholar
  142. Grecksch G, Bernstein HG, Becker A, Hollt V, Bogerts B (1999) Disruption of latent inhibition in rats with postnatal hippocampal lesions. Neuropsychopharmacology 20:525–532CrossRefPubMedGoogle Scholar
  143. Groenewegen HJ, Vermeulen-Van der Zee E, te Kortschot A, Witter MP (1987) Organization of the projections from the subiculum to the ventral striatum in the rat. A study using anterograde transport of phaseolus vulgaris leucoagglutinin. Neuroscience 23:103–120Google Scholar
  144. Groenewegen HJ, Berendse HW, Wolters JG, Lohman AHM (1990) The anatomical relationship of the prefrontal cortex with the striatopallidal system, the thalamus and the amygdala: evidence for a parallel organization. Prog Brain Res 85:95–118PubMedGoogle Scholar
  145. Groenewegen HJ, Berendse HW, Meredith GE, Haber SN, Voorn P, Wolters JG, Lohman AHM (1991) Functional anatomy of the ventral, limbic system-innervated striatum. In: Willner P, Scheel-Kruger J (eds) The mesolimbic dopamine system: from motivation to action. Wiley, Chinchester, pp 19–60Google Scholar
  146. Groenewegen HJ, Wright CI, Beijer AVJ (1996) The nucleus accumbens: gateway for limbic structures to reach the motor system? Prog Brain Res 107:485–511PubMedGoogle Scholar
  147. Groenewegen HG, Wright CI, Beijer VJ, Voorn P (1999) Convergence and segregation of ventral striatal inputs and outputs. In: McGintry JF (ed) Advancing from the ventral striatum to the extended amygdala. Ann NY Acad Sci 877:49–64PubMedGoogle Scholar
  148. Gur RE, Petty RG, Turetsky BI, Gur RC (1996) Schizophrenia throughout life: Sex differences in severity and profile of symptoms. Schizophr Res 21:1–12CrossRefPubMedGoogle Scholar
  149. Halberstadt AL (1995) The phencyclidine-glutamate model of schizophrenia. Clin Neuropharmacol 18:237–249PubMedGoogle Scholar
  150. Hall G (1991) Perceptual and associative learning. Oxford University Press, New YorkGoogle Scholar
  151. Hall G, Channell S (1985) Latent inhibition and conditioning after pre-exposure to the training context. Learn Motiv 16:381–397Google Scholar
  152. Hall RC, Popkin MK, Beresford TP, Hall AK (1988) Amphetamine psychosis: clinical presentations and differential diagnosis. Psychiatr Med 6:73–79Google Scholar
  153. Han JS, Gallagher M, Holland P (1995) Hippocampal lesions disrupt decrements but not increments in conditioned stimulus processing. J Neurosci 15:7323–7329Google Scholar
  154. Harrison PJ (1999) The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 122:593–624CrossRefPubMedGoogle Scholar
  155. Heimer L, Alheid GF, de Olmos JS, Groenewegen HJ, Haber SN, Harlan RE, Zahm DS (1997) The accumbens: beyond the core-shell dichotomy. J Neuropsychiatr Clin Neurosci 9:354–381Google Scholar
  156. Heinz A, Knable MB, Coppola R, Gorey JG, Jones DW, Lee KS, Weinberger DR (1998) Psychomotor slowing, negative symptoms and dopamine receptor availability—an IBZM SPECT study in neuroleptic-treated and drug-free schizophrenic. Schizophr Res 31:19–26PubMedGoogle Scholar
  157. Hemsley DR (1993) A simple (or simplistic?) cognitive model for schizophrenia. Behav Res Ther 31:633–645CrossRefPubMedGoogle Scholar
  158. Hemsley DR (1994) Cognitive disturbance as the link between schizophrenic symptoms and their biological bases. Neurol Psychiatry Brain Res 2:163–170Google Scholar
  159. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Horowitz A, Kelly D (1996) Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry 169: 610–617PubMedGoogle Scholar
  160. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M (1999) Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 56:29–36PubMedGoogle Scholar
  161. Hernandez-Lopez S, Bargas J, Surmeier DJ, Reyes A, Galarraga E (1997) D1 receptor activation enhances evoked discharge in neostriatal medium spiny neurons by modulating an L-type Ca2+ conductance. J Neurosci 17:3345–3353Google Scholar
  162. Hertel P, Lindblom N, Nomikos GG, Svensson TH (1998) Modulation of central serotonergic neurotransmission by risperidone: underlying mechanism(s) and significance of action. Prog Neuropsychopharmacol Biol Psychiatry 22:815–834CrossRefPubMedGoogle Scholar
  163. Hietala J, Syvalahti E, Vuorio K, Rakkolainen V, Bergman J, Haaparanta M, Solin O, Kuoppamaki M, Kirvela O, Ruotsalainen U et al. (1995) Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet 347:1130–1131Google Scholar
  164. Hietala J, Syvalahti E, Vilkman H, Vuorio K, Rakkolainen V, Bergman J, Haaparanta M, Solin O, Kuoppamaki M, Eronen E, Ruotsalainen U, Salokangas RK (1999) Depressive symptoms and presynaptic dopamine function in neuroleptic- naive schizophrenia. Schizophr Res 35:41–50CrossRefPubMedGoogle Scholar
  165. Hitchcock JM, Lister S, Fischer TR, Wettstein JG (1997) Disruption of latent inhibition in the rat by the 5-HT2 agonist DOI: effects of MDL 100,907, clozapine, risperidone and haloperidol. Behav Brain Res 88:43–49PubMedGoogle Scholar
  166. Hoehn-Saric R, McLeod DR, Glowa JR (1991) The effects of NMDA receptor blockade on the acquisition of a conditioned emotional response. Biol Psychiatry 30:170–176PubMedGoogle Scholar
  167. Holland PC, Gallagher M (1999) Amygdala circuitry in attentional and representational processes. Trends Cognit Sci 3:65–73CrossRefGoogle Scholar
  168. Holt W, Maren S (1999) Muscimol inactivation of the dorsal hippocampus impairs contextual retrieval of fear memory. J Neurosci 19:9054–9062Google Scholar
  169. Honey RC, Good M (1993) Selective hippocampal lesions abolish the contextual specificity of latent inhibition and conditioning. Behav Neurosci 107:23–33PubMedGoogle Scholar
  170. Hutcheson DM, Parkinson JA, Robbins TW, Everitt BJ (2001) The effects of nucleus accumbens core and shell lesions on intravenous heroin self-administration and the acquisition of drug-seeking behaviour under a second-order schedule of heroin reinforcement. Psychopharmacology 153:464–472CrossRefPubMedGoogle Scholar
  171. Ichikawa J, Meltzer HY (1999) Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs. Eur Arch Psychiatr Clin Neurosci 249:90–98Google Scholar
  172. Ichikawa J, Meltzer HY (2000) The effect of serotonin(1A) receptor agonism on antipsychotic drug- induced dopamine release in rat striatum and nucleus accumbens. Brain Res 858:252–263PubMedGoogle Scholar
  173. Ichikawa J, Kuroki T, Kitchen MT, Meltzer HY (1995) R(+)-8-OH-DPAT, a 5-HT1A receptor agonist, inhibits amphetamine-induced dopamine release in rat striatum and nucleus accumbens. Eur J Pharmacol 287:179–184CrossRefPubMedGoogle Scholar
  174. Ichikawa J, Kuroki T, Dai J, Meltzer HY (1998) Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens. Eur J Pharmacol 352:163–171CrossRefGoogle Scholar
  175. Ito R, Dalley JW, Howes SR, Robbins TW, Everitt BJ (2000) Dissociation in conditioned dopamine release in the nucleus accumbens core and shell in response to cocaine cues and during cocaine-seeking behavior in rats. J Neurosci 20:7489–7495PubMedGoogle Scholar
  176. Izumoto Y, Inoue S, Yasuda N (1999) Schizophrenia and the influenza epidemics of 1957 in Japan. Biol Psychiatry 46:119–124CrossRefPubMedGoogle Scholar
  177. Jackson ME, Moghaddam B (2001) Amygdala regulation of nucleus accumbens dopamine output is governed by the prefrontal cortex. J Neurosci 21:676–681PubMedGoogle Scholar
  178. Jacobs BL, Fornal CA (1995) Serotonin and behavior: a general hypothesis. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: the fourth generation of progress. Raven Press, New YorkGoogle Scholar
  179. Jakob H, Beckmann H (1986) Prenatal developmental disturbances in the limbic allocortex in schizophrenics. J Neural Transm 65:303–327PubMedGoogle Scholar
  180. Janowsky DS, Davis JM (1976) Methylphenidate, dextroamphetamine, and levamfetamine: effects on schizophrenic symptoms. Arch Gen Psychiatry 33:304–308PubMedGoogle Scholar
  181. Jarskog LF, Xiao H, Wilkie MB, Lauder JM, Gilmore JH (1997) Cytokine regulation of embryonic rat dopamine and serotonin neuronal survival in vitro. Int J Dev Neurosci 15:711–716CrossRefPubMedGoogle Scholar
  182. Javitt DC (1987) Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. Hillside J Clin Psychiatry 9:12–35PubMedGoogle Scholar
  183. Javitt DC, Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301–1308PubMedGoogle Scholar
  184. Javitt DC, Sershen H, Hashim A, Lajtha A (1997) Reversal of phencyclidine-induced hyperactivity by glycine and the glycine uptake inhibitor glycyldodecylamide. Neuropsychopharmacology 17:202–204CrossRefPubMedGoogle Scholar
  185. Javitt DC, Balla A, Sershen H, Lajtha A (1999) Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors. Biol Psychiatry 45:668–679PubMedGoogle Scholar
  186. Jeanblanc J, Hoeltzel A, Louilot A (2002a) Dissociation in the involvement of dopaminergic neurons innervating the core and shell subregions of the nucleus accumbens in latent inhibition and affective perception. Neuroscience 111:315–323CrossRefPubMedGoogle Scholar
  187. Jeanblanc J, Hoeltzel A, Louilot A (2002b) Differential involvement of dopaminergic neurons innervating the anterior part and posterior parts of the striatum in latent inhibition. Program No.281.18 Society for Neuroscience OnlineGoogle Scholar
  188. Jentsch JD, Roth RH (1999) The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20:201–225PubMedGoogle Scholar
  189. Jentsch JD, Taylor JR (2001) Impaired inhibition of conditioned responses produced by subchronic administration of phencyclidine to rats. Neuropsychopharmacology 24:66–74CrossRefPubMedGoogle Scholar
  190. Joel D, Weiner I, Feldon J (1997) Electrolytic lesions of the medial prefrontal cortex in rats disrupt performance on an analog of Wisconsin Card Sorting Test but do not disrupt latent inhibition: implications for animal models of schizophrenia. Behav Brain Res 85:187–201CrossRefPubMedGoogle Scholar
  191. Johnstone EC, Crow TJ, Frith CD, Carney MW, Price JS (1978) Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet 1:848–851Google Scholar
  192. Jongen-Relo AL, Kaufmann S, Feldon J (2002) A differential involvement of the shell and core subterritories of the nucleus accumbens of rats in attentional processes. Neuroscience 111:95–109CrossRefPubMedGoogle Scholar
  193. Joseph MH, Peters SL, Gray JA (1993) Nicotine blocks latent inhibition in rats: evidence for a critical role of increased functional activity of dopamine in the mesolimbic system at conditioning rather than pre-exposure. Psychopharmacology 110:187–192PubMedGoogle Scholar
  194. Joseph MH, Peters SL, Moran PM, Grigoryan GA, Young AM, Gray JA (2000) Modulation of latent inhibition in the rat by altered dopamine transmission in the nucleus accumbens at the time of conditioning. Neuroscience 101:921–930CrossRefPubMedGoogle Scholar
  195. Kabat K, Buterbaugh GG, Eccles CU (1985) Methylazoxymethanol as a developmental model of neurotoxicity. Neurobehav Toxicol Teratol 7:519–525PubMedGoogle Scholar
  196. Kane JM (1995) Current problems with the pharmacotherapy of schizophrenia. Clin Neuropharmacol 18:S154–S161Google Scholar
  197. Kapur S, Remington G (1996) Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153:466–476PubMedGoogle Scholar
  198. Karnath HO, Wallesch CW (1992) Inflexibility of mental planning: a characteristic disorder with prefrontal lobe lesions? Neuropsychologia 30:1011–1016CrossRefPubMedGoogle Scholar
  199. Kasprow WJ, Catterson D, Schachtman TR, Miller RR (1984) Attenuation of latent inhibition by post-acquisition reminder. Q J Exp Psychol 36B:53–64Google Scholar
  200. Kaye H, Pearce JM (1987a) Hippocampal lesions attenuate latent inhibition and the decline of the orienting response in rats. Q J Exp Psychol 39B:107–125Google Scholar
  201. Kaye H, Pearce JM (1987b) Hippocampal lesions attenuate latent inhibition of a CS and of a neutral stimulus. Psychobiology 15:293–299Google Scholar
  202. Kelley AE, Smith-Roe SL, Holahan MR (1997) Response-reinforcement learning is dependent on N-methyl-d-aspartate receptor activation in the nucleus accumbens core. Proc Natl Acad Sci USA 94:12174–12179PubMedGoogle Scholar
  203. Kendell RE, Kemp IW (1989) Maternal influenza in the etiology of schizophrenia. Arch Gen Psychiatry 46:878–882PubMedGoogle Scholar
  204. Killcross AS, Robbins TW (1993) Differential effects of intra-accumbens and systemic amphetamine on latent inhibition using an on-baseline, within-subject conditioned suppression paradigm. Psychopharmacology 110:479–489Google Scholar
  205. Killcross AS, Dickinson A, Robbins TW (1994a) Amphetamine-induced disruptions of latent inhibition are reinforcer mediated: implications for animal models of schizophrenic attentional dysfunction. Psychopharmacology 115:185–195Google Scholar
  206. Killcross AS, Dickinson A, Robbins TW (1994b) Effects of the neuroleptic alpha-flupenthixol on latent inhibition in aversively- and appetitively-motivated paradigms: evidence for dopamine-reinforcer interactions. Psychopharmacology 115:196–205PubMedGoogle Scholar
  207. Killcross AS, Stanhope KJ, Dourish CT, Piras G (1997) WAY 100635 and latent inhibition in the rat: selective effects at pre-exposure. Behav Brain Res 88:51–57CrossRefPubMedGoogle Scholar
  208. Kim JJ, DeCola JP, Landeira-Fernandez J, Fanselow MS (1991) N-Methyl-d-aspartate receptor antagonist APV blocks acquisition but not expression of fear conditioning. Behav Neurosci 105:126–133PubMedGoogle Scholar
  209. Kimura M, Toth LA, Agostini H, Cady AB, Majde JA, Krueger JM (1994) Comparison of acute phase responses induced in rabbits by lipopolysaccharide and double-stranded RNA. Am J Physiol 267:R1596–R1605PubMedGoogle Scholar
  210. Kinon BJ, Lieberman JA (1996) Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology 124:2–34PubMedGoogle Scholar
  211. Konstandi M, Kafetzopoulos E (1993) Effects of striatal or accumbens lesions on the amphetamine-induced abolition of latent inhibitions. Pharmacol Biochem Behav 44:751–754CrossRefPubMedGoogle Scholar
  212. Koob, GF, Riley, SJ, Smith, SC, Robbins, TW (1978) Effects of 6-hydroxydopamine lesions of the nucleus accumbens septi and olfactory tubercle on feeding, locomotor activity, and amphetamine anorexia in the rat. J Comp Physiol Psychol. 92:917–927Google Scholar
  213. Kornetzky C (1972) The use of simple test of attention as a measure of drug effects in schizophrenic patients. Psychopharmacology 24:99–106Google Scholar
  214. Kovelman JA, Scheibel AB (1984) A neurohistological correlate of schizophrenia. Biol Psychiatry 19:1601–1621PubMedGoogle Scholar
  215. Kraepelin E (1919) Dementia praecox and paraphrenia. Kreiger, New YorkGoogle Scholar
  216. Kumari V, Cotter PA, Mulligan OF, Checkley SA, Gray NS, Hemsley DR, Thornton JC, Corr PJ, Toone BK, Gray JA (1999) Effects of d-amphetamine and haloperidol on latent inhibition in healthy male volunteers. J Psychopharmacol 13:398–405Google Scholar
  217. Lacroix L, Broersen LM, Weiner I, Feldon J (1998) The effects of excitotoxic lesion of the medial prefrontal cortex on latent inhibition, prepulse inhibition, food hoarding, elevated plus maze, active avoidance and locomotor activity in the rat. Neuroscience 84:432–443CrossRefGoogle Scholar
  218. Lacroix L, Broersen LM, Feldon J, Weiner I (2000a) Effects of local infusions of dopaminergic drugs into the medial prefrontal cortex of rats on latent inhibition, prepulse inhibition and amphetamine induced activity. Behav Brain Res 107:111–121PubMedGoogle Scholar
  219. Lacroix L, Spinelli S, White W, Feldon J (2000b) The effects of ibotenic acid lesions of the medial and lateral prefrontal cortex on latent inhibition, prepulse inhibition and amphetamine-induced hyperlocomotion. Neuroscience 97:459–468Google Scholar
  220. Lanfumey L, Hamon M (2000) Central 5-HT(1A) receptors: regional distribution and functional characteristics. Nucl Med Biol 27:430–436Google Scholar
  221. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB (1996) Single photon emission computerized tomography imaging of amphetamine- induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 93:9235–9240PubMedGoogle Scholar
  222. Laruelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R (1999) Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry 46:56–72PubMedGoogle Scholar
  223. LeDoux JE (1992) Brain mechanisms of emotion and emotional learning. Curr Opin Neurobiol 2:191–197PubMedGoogle Scholar
  224. Lehmann J, Stohr T, Schuller J, Domeney A, Heidbreder C, Feldon J (1998) Long-term effects of repeated maternal separation on three different latent inhibition paradigms. Pharmacol Biochem Behav 59:873–882PubMedGoogle Scholar
  225. Lehmann J, Pryce CR, Bettschen D, Feldon J (1999) The maternal separation paradigm and adult emotionality and cognition in male and female Wistar rats. Pharmacol Biochem Behav 64:705–715PubMedGoogle Scholar
  226. Lehmann J, Stohr T, Feldon J (2000) Long-term effects of prenatal stress experiences and postnatal maternal separation on emotionality and attentional processes. Behav Brain Res 107:133–144PubMedGoogle Scholar
  227. Le Moal M, Simon H (1991) Mesocorticolimbic dopaminergic network: Functional and regulatory roles. Physiol Rev 71:155–234PubMedGoogle Scholar
  228. Leysen JE, Janssen PMF, Schotte A, Luyten WHML, Megens AAHP (1993) Interaction of antipsychotic drugs with neurotransmitter receptor sites invitro and in-vivo in relation to pharmacological and clinical effects—role of 5HT(2) receptors. Psychopharmacology 112:S40–S54Google Scholar
  229. Lieberman JA, Kane JM, Gadaleta D, Brenner R, Lesser MS, Kinon B (1984) Methylphenidate challenge as a predictor of relapse in schizophrenia. Am J Psychiatry 141:633–638PubMedGoogle Scholar
  230. Lieberman JA, Kane JM, Alvir J (1987) Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology 91:416–434Google Scholar
  231. Lieberman JA, Mailman RB, Duncan G, Sikich L, Chakos M, Nichols DE, Kraus JE (1998) Serotonergic basis of antipsychotic drug effects in schizophrenia. Biol Psychiatry 44:1099–1117PubMedGoogle Scholar
  232. Lieberman JA, Perkins D, Belger A, Chakos M, Jarskog F, Boteva K, Gilmore J (2001) The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry 50:884–897CrossRefPubMedGoogle Scholar
  233. Lindstrom LH, Gefvert O, Hagberg G, Lundberg T, Bergstrom M, Hartvig P, Langstrom B (1999) Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by l-(beta-11C)-DOPA and PET. Biol Psychiatry 46:681–688CrossRefPubMedGoogle Scholar
  234. Lipp OV, Vaitl D (1992) Latent inhibition in human Pavlovian differential conditioning: effect of additional stimulation after pre-exposure and relation to schizotypal traits. Person Indiv Diff 13:1003–1012CrossRefGoogle Scholar
  235. Lipska BK, Weinberger DR (2000) To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 23:223–239PubMedGoogle Scholar
  236. Lorden JF, Rickert EJ, Berry DW (1983) Forebrain monoamines and associative learning: I. Latent inhibition and conditioned inhibition. Behav Brain Res 9:181–199PubMedGoogle Scholar
  237. Loskutova LV (1998) The site of action of the serotoninergic system in the two-stage process of formation of latent inhibition in rats. Zh Vyssh Nerv Deiat 48:349–344Google Scholar
  238. Loskutova LV (2001) The effect of a serotoninergic substrate of the nucleus accumbens on the latent inhibition. Neurosci Behav Physiol 31:15–20PubMedGoogle Scholar
  239. Louilot A, Besson C (2000) Specificity of amygdalostriatal interactions in the involvement of mesencephalic dopaminergic neurons in affective perception. Neuroscience 96:73–82PubMedGoogle Scholar
  240. Louilot A, Simon H, Taghzouti K, Le Moal M (1985) Modulation of dopaminergic activity in the nucleus accumbens following facilitation or blockade of the dopaminergic transmission in the amygdala: a study by in vivo differential pulse voltammetry. Brain Res 347:141–145Google Scholar
  241. Lubow RE (1973) Latent inhibition. Psychol Bull 79:398–408PubMedGoogle Scholar
  242. Lubow RE (1989) Latent inhibition and conditioned attention theory. Cambridge University Press, New YorkGoogle Scholar
  243. Lubow RE, De la Casa G (2002) Latent inhibition as a function of schizotypality and gender: implications for schizophrenia. Biol Psychol 59:69–86CrossRefPubMedGoogle Scholar
  244. Lubow RE, Gewirtz JC (1995) Latent inhibition in humans: data, theory, and implications for schizophrenia. Psychol Bull 117:87–103CrossRefPubMedGoogle Scholar
  245. Lubow RE, Weiner I, Schnur P (1981) Conditioned attention theory. In: Bower GH (ed) The psychology of learning and motivation, vol 15. Academic Press, New York, pp 1–49Google Scholar
  246. Lubow RE, Ingberg-Sachs Y, Zalstein-Orda N, Gewirtz JC (1992) Latent inhibition in low and high "psychotic-prone" subjects. Person Indiv Diff 13:563–572CrossRefGoogle Scholar
  247. Lubow RE, Kaplan O, Abramovich P, Rudnick A, Laor N (2000) Visual search in schizophrenia: latent inhibition and novel pop-out effects. Schizophr Res 45:145–156CrossRefPubMedGoogle Scholar
  248. Lubow RE, Kaplan O, De la Casa G (2001) Performance on the visual search analog of latent inhibition is modulated by an interaction between schizotypy and gender. Schizophr Res 52:275–287CrossRefPubMedGoogle Scholar
  249. Lucki I (1998) The spectrum of behaviors influenced by serotonin. Biol Psychiatry 44:151–162PubMedGoogle Scholar
  250. Lyon M (1991) Animal models of mania and schizophrenia. In: Willner P (ed) Behavioral models in psychopharmacology: theoretical, industrial and clinical perspectives. Cambridge University Press, Cambridge, pp 253–310Google Scholar
  251. Mackintosh NJ (1975) A theory of attention: Variations in the associability of stimuli with reinforcement. Psychol Rev 82:276–298Google Scholar
  252. Magaro PA (1980) Cognition in schizophrenia and paranoia: the integration of cognitive processes. Erlbaum, Hillsdale, N.J.Google Scholar
  253. Maher BA, Manschreck TC, Molino MA (1983) Redundancy, pause distributions and thought disorder in schizophrenia. Lang Speech 26:191–199PubMedGoogle Scholar
  254. Maldonado-Irizarry CS, Kelley AE (1994) Differential behavioral effects following microinjection of an NMDA antagonist into nucleus accumbens subregions. Psychopharmacology 116:65–72PubMedGoogle Scholar
  255. Maldonado-Irizarry CS, Kelley AE (1995) Excitotoxic lesions of the core and shell subregions of the nucleus accumbens differentially disrupt body weight regulation and motor activity in rat. Brain Res Bull 38:551–559CrossRefPubMedGoogle Scholar
  256. Marcus MM, Nomikos GG, Svensson TH (2000) Effects of atypical antipsychotic drugs on dopamine output in the shell and core of the nucleus accumbens: role of 5-HT(2A) and alpha(1)-adrenoceptor antagonism. Eur Neuropsychopharmacol 10:245–253CrossRefPubMedGoogle Scholar
  257. Marek GJ, Aghajanian GK (1998) The electrophysiology of prefrontal serotonin systems: therapeutic implications for mood and psychosis. Biol Psychiatry 44:1118–1127PubMedGoogle Scholar
  258. Maren S, Holt W (2000) The hippocampus and contextual memory retrieval in Pavlovian conditioning. Behav Brain Res 110:97–108PubMedGoogle Scholar
  259. Marenco S, Weinberger DR (2000) The neurodevelopmental hypothesis of schizophrenia: following a trail of evidence from cradle to grave. Dev Psychopathol 12:501–527CrossRefPubMedGoogle Scholar
  260. Martin-Ruiz R, Puig MV, Celada P, Shapiro DA, Roth BL, Mengod G, Artigas F (2001) Control of serotonergic function in medial prefrontal cortex by serotonin-2A receptors through a glutamate-dependent mechanism. J Neurol 21:9856–9866Google Scholar
  261. Marx CE, Jarskog LF, Lauder JM, Lieberman JA, Gilmore JH (2001) Cytokine effects on cortical neuron MAP-2 immunoreactivity: implications for schizophrenia. Biol Psychiatry 50:743–749CrossRefPubMedGoogle Scholar
  262. Mathe JM, Schilstrom B, Nomikos GG, Svensson TH (1998) Non-NMDA receptors in the ventral tegmental area mediate systemic dizocilpine (MK-801) induced hyperlocomotion and dopamine release in the nucleus accumbens. J Neurosci Res 51:583–592PubMedGoogle Scholar
  263. Mathe JM, Nomikos GG, Blakeman KH, Svensson TH (1999) Differential actions of dizocilpine (MK-801) on the mesolimbic and mesocortical dopamine systems: role of neuronal activity. Neuropharmacology 38:121–128CrossRefPubMedGoogle Scholar
  264. McAllister KH (1997) A single administration of d-amphetamine prior to stimulus pre-exposure and conditioning attenuates latent inhibition. Psychopharmacology 130:79–84CrossRefPubMedGoogle Scholar
  265. McCartan D, Bell R, Green JF, Campbell C, Trimble K, Pickering A, King DJ (2001) The differential effects of chlorpromazine and haloperidol on latent inhibition in healthy volunteers. J Psychopharmacol 15:96–104PubMedGoogle Scholar
  266. McGhie A, Chapman J (1961) Disorders of attention and perception in early schizophrenia. Br J Med Psychol 34:103–116Google Scholar
  267. Mednick SA, Huttunen MO, Machon RA (1994) Prenatal influenza infections and adult schizophrenia. Schizophr Bull 20:263–267PubMedGoogle Scholar
  268. Meltzer HY (1989) Clinical studies on the mechanism of action of clozapine: The dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 99:S18–S27PubMedGoogle Scholar
  269. Meltzer HY (1999) The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21:106S–115SPubMedGoogle Scholar
  270. Meltzer HY, Nash JF (1991) Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev 43:587–604PubMedGoogle Scholar
  271. Meltzer HY, Stahl SM (1986) The dopamine hypothesis of schizophrenia: a review. Schizophr Bull 2:19–76Google Scholar
  272. Meltzer HY, Sommers AA, Luchins DJ (1986) The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia. J Clin Psychopharmacol 6:330–339Google Scholar
  273. Miller RR, Kasprow WJ, Schachtman TR (1986) Retrieval variability: sources and consequences. Am J Psychol 99:145–218PubMedGoogle Scholar
  274. Moghaddam B, Adams BW (1998) Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281:1350–1353CrossRefGoogle Scholar
  275. Moghaddam B, Adams B, Verma A, Daly D (1997) Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17:2921–2927PubMedGoogle Scholar
  276. Moore JW, Stickney KJ (1980) Formation of attentional-associative networks in real time: role of the hippocampus and implications for conditioning. Physiol Psychol 8:207–217Google Scholar
  277. Moore H, West AR, Grace AA (1999) The regulation of forebrain dopamine transmission: relevance to the pathophysiology and psychopathology of schizophrenia. Biol Psychiatry 46:40–55PubMedGoogle Scholar
  278. Moran PM, Fischer TR, Hitchcock JM, Moser PC (1996) Effects of clozapine on latent inhibition in the rat. Behav Pharmacol 7:42–48PubMedGoogle Scholar
  279. Moser PC, Moran PM, Frank RA, Kehne JH (1996) Reversal of amphetamine-induced behaviours by MDL 100,907, a selective 5-HT2A antagonist. Behav Brain Res 73:163–167PubMedGoogle Scholar
  280. Moser PC, Hitchcock JM, Lister S, Moran PM (2000) The pharmacology of latent inhibition as an animal model of schizophrenia. Brain Res Rev 33:275–307PubMedGoogle Scholar
  281. Muller N, Ackenheil M (1998) Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 22:1–33CrossRefPubMedGoogle Scholar
  282. Murphy CA, Pezze M, Feldon J, Heidbreder C (2000) Differential involvement of dopamine in the shell and core of the nucleus accumbens in the expression of latent inhibition to an aversively conditioned stimulus. Neuroscience 97:469–477PubMedGoogle Scholar
  283. Murphy CA, Fend M, Russig H, Feldon J (2001) Latent inhibition, but not prepulse inhibition, is reduced during withdrawal from an escalating dosage schedule of amphetamine. Behav Neurosci 115:1247–1256PubMedGoogle Scholar
  284. Murray RM, Fearon P (1999) The developmental 'risk factor' model of schizophrenia. J Psychiatr Res 33:497–499CrossRefPubMedGoogle Scholar
  285. Murray RM, Lewis SW (1987) Is schizophrenia a nerodevelopmental disorder? Br Med J 295:681–682Google Scholar
  286. Myers CE, Gluck MA (1994) Context, conditioning, and hippocampal rerepresentation in animal learning. Behav Neurosci 108:835–847CrossRefPubMedGoogle Scholar
  287. Nakamura K, Kurasawa M (2000) Serotonergic mechanisms involved in the attentional and vigilance task performance of rats and the palliative action of aniracetam. Naunyn Schmiedeberg's Arch Pharmacol 362:521–528Google Scholar
  288. Nawa H, Takahashi M, Patterson PH (2000) Cytokine and growth factor involvement in schizophrenia—support for the developmental model. Mol Psychiatry 5:594–603CrossRefPubMedGoogle Scholar
  289. Nicholson DA, Freeman JH Jr (2002) Medial dorsal thalamic lesions impair blocking and latent inhibition of the conditioned eyeblink response in rats. Behav Neurosci 116:276–285CrossRefPubMedGoogle Scholar
  290. Nilsson M, Carlsson A, Carlsson ML (1997) Glycine and d-serine decrease MK-801-induced hyperactivity in mice. J Neural Transm 104:1195–1205PubMedGoogle Scholar
  291. Noda Y, Yamada K, Furukawa H, Nabeshima T (1995) Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: a new model of schizophrenia. Br J Pharmacol 116:2531–2537PubMedGoogle Scholar
  292. Nuechterlein KH, Dawson ME (1984) Information processing and attentional functioning in the developmental course of the schizophrenic disorder. Schizophr Bull 10:160–203PubMedGoogle Scholar
  293. O'Callaghan E, Sham PC, Takei N, Murray G, Glover G, Hare EH, Murray RM (1994): the relationship of schizophrenic births to 16 infectious diseases. Br J Psychiatry 165:354–356Google Scholar
  294. Oades RD (1982) Attention and schizophrenia: Neurobiological bases. Pitman, LondonGoogle Scholar
  295. Oades RD (1985) The role of noradrenaline in tuning and dopamine in switching between signals in the CNS. Neurosci Biobehav Rev 9:261–282PubMedGoogle Scholar
  296. Oberling P, Gosselin O, Miller RR (1999) Latent inhibition in animals as a model of acute schizophrenia. In: Haugh M, Whalen RE (eds) Animal models of human emotion and cognition. American Psychological Association, Washington, D.C., pp 87–102Google Scholar
  297. O'Donnell P, Grace AA (1998) Dysfunctions in multiple interrelated systems as the neurobiological bases of schizophrenic symptom clusters. Schizophr Bull 24:267–283Google Scholar
  298. Ogura C, Kishimoto A, Nakao T (1976) Clinical effect of L-dopa on schizophrenia. Curr Ther Res Clin Exp 20:308–318PubMedGoogle Scholar
  299. Olney JW, Farber NB (1995) NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia. Neuropsychopharmacology 13:335–345CrossRefPubMedGoogle Scholar
  300. Otake K, Nakamura Y (2000) Possible pathways through which neurons of the shell of the nucleus accumbens influence the outflow of the core of the nucleus accumbens. Brain Dev 22:S17–26PubMedGoogle Scholar
  301. Pallares MA, Nadal RA, Silvestre JS, Ferre NS (1995) Effects of ketamine, a noncompetitive NMDA antagonist, on the acquisition of the lever-press response in rats. Physiol Behav 57:389–392CrossRefPubMedGoogle Scholar
  302. Pantelis C, Barber FZ, Barnes TR, Nelson HE, Owen AM, Robbins TW (1999) Comparison of set-shifting ability in patients with chronic schizophrenia and frontal lobe damage. Schizophr Res 37:251–270PubMedGoogle Scholar
  303. Parkinson JA, Olmstead MC, Burns LH, Robbins TW, Everitt BJ (1999) Dissociation in effects of lesions of the nucleus accumbens core and shell on appetitive Pavlovian approach behavior and the potentiation of conditioned reinforcement and locomotor activity by d-amphetamine. J Neurosci 19:2401–2412PubMedGoogle Scholar
  304. Parkinson JA, Cardinal RN, Everitt BJ (2000) Limbic cortical-ventral striatal systems underlying appetitive conditioning. Prog Brain Res 126:263–285PubMedGoogle Scholar
  305. Paulson PE, Robinson TE (1996) Regional differences in the effects of amphetamine withdrawal on dopamine dynamics in the striatum. Analysis of circadian patterns using automated on-line microdialysis. Neuropsychopharmacology 14:326–338CrossRefGoogle Scholar
  306. Pawlowski L, Mathe JM, Svensson TH (1990) Phencyclidine activates rat A10 dopamine neurons but reduces burst activity and causes regularization. Acta Physiol Scand 139:529–530PubMedGoogle Scholar
  307. Payne RW (1966) The measurement and significance of overinclusive thinking and retardation in schizophrenic patients. In: Hoch P, Zubin J (eds) Psychopathology of schizophrenia. Grune and Stratton, New YorkGoogle Scholar
  308. Pearce BD (2000) Viral mechanisms of schizophrenia. In: Myslobodsky MS, Weiner I (eds) Contemporary issues in modeling psychopathology. Kluwer, Dordrecht, pp 79–102Google Scholar
  309. Pearce JM, Hall G (1980) A model for Pavlovian learning: variations in the effectiveness of conditioned but not of unconditioned stimuli. Psychol Rev 87:532–552Google Scholar
  310. Pennartz CM, Groenewegen HJ, Lopes da Silva FH (1994) The nucleus accumbens as a complex of functionally distinct neuronal ensembles: an integration of behavioural, electrophysiological and anatomical data. Prog Neurobiol 42:719–761PubMedGoogle Scholar
  311. Peters SL, Joseph MH (1993) Haloperidol potentiation of latent inhibition in rats: evidence for a critical role at conditioning rather than pre-exposure. Behav Pharmacol 4:183–186PubMedGoogle Scholar
  312. Pierce RC, Kalivas PW (1997) A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res Rev 25:192–216Google Scholar
  313. Phillips RG, LeDoux JE (1992) Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning. Behav Neurosci 106:274–285PubMedGoogle Scholar
  314. Phillips RG, LeDoux JE (1995) Lesions of the fornix but not the entorhinal or perirhinal cortex interfere with contextual fear conditioning. J Neurosci 15:5308–5315Google Scholar
  315. Pouzet B, Veenman CL, Yee BK, Feldon J, Weiner I (1999) The effects of radiofrequency lesion or transection of the fimbria- fornix on latent inhibition in the rat. Neuroscience 91:1355–1368PubMedGoogle Scholar
  316. Purves D, Bonardi C, Hall G (1995) Enhancement of latent inhibition in rats with electrolytic lsions of the hippocampus. Behav Neurosci 109:367–371Google Scholar
  317. Rappaport M, Silverman J, Hopkins HK, Hall K (1971) Phenotiazine effects on auditory signal detection in paranoids and paranoid schizophrenics. Science 174:723–725PubMedGoogle Scholar
  318. Rascle C, Mazas O, Vaiva G, Tournant M, Raybois O, Goudemand M, Thomas P (2001) Clinical features of latent inhibition in schizophrenia. Schizophr Res 51:149–161CrossRefPubMedGoogle Scholar
  319. Redgrave P, Prescott TJ, Gurney K (1999) The basal ganglia: a vertebrate solution to the selection problem? Neuroscience 89:1009–1023Google Scholar
  320. Reilly S, Harley C, Revusky S (1993) Ibotanate lesions of the hippocampus enhance latent inhibition in conditioned taste aversion and increase resistance to extinction in conditioned taste preference. Behav Neurosci 107:996–1004PubMedGoogle Scholar
  321. Reiss S, Wagner A (1972) CS habituation produces a "latent inhibition" effect but no active "conditioned inhibition". Learn Motiv 3:237–245Google Scholar
  322. Reith J, Benkelfat C, Sherwin A, Yasuhara Y, Kuwabara H, Andermann F, Bachneff S, Cumming P, Diksic M, Dyve SE, et al. (1994) Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci USA 91:11651–11654PubMedGoogle Scholar
  323. Rescorla RA (1969) Pavlovian conditioned inhibition. Psychol Bull 72:77–94Google Scholar
  324. Rescorla RA (1971) Summation and retardation tests of latent inhibition. J Comp Physiol Psychol 75:77–81PubMedGoogle Scholar
  325. Restivo L, Passino E, Middei S, Ammassari-Teule M (2002) The strain-specific involvement of nucleus accumbens in latent inhibition might depend on differences in processing configural- and cue-based information between C57BL/6 and DBA mice. Brain Res Bull 57:35–39CrossRefPubMedGoogle Scholar
  326. Robbins TW (1991) Cognitive deficits in schizophrenia and Parkinson's disease—neural basis and the role of dopamine. In: Willner P, J. Scheel-Kruger J (eds) The mesolimbic dopamine system—from motivation to action. Wiley, ChichesterGoogle Scholar
  327. Robbins TW (1997) Arousal systems and attentional processes. Biol Psychol 45:57–71PubMedGoogle Scholar
  328. Robbins TW, Everitt BJ (1982) Functional studies of the central catecholamines. Int Rev Neurobiol 23:303–365PubMedGoogle Scholar
  329. Robbins TW, Everitt BJ (1992) Function of dopamine in the dorsal and ventral striatum. Semin Neurosci 4: Google Scholar
  330. Robbins TW, Everitt BJ (1996) Neurobehavioural mechanisms of reward and motivation. Curr Opin Neurobiol 6:228–236PubMedGoogle Scholar
  331. Robbins TW, Koob GF (1980) Selective disruption of displacement behaviour by lesions of the mesolimbic dopamine system. Nature 285:410–413Google Scholar
  332. Robbins TW, Sahakian BJ (1983) Behavioural effects of psychomotor stimulant drugs: clinical and neuropsychological implications. In: Creese I (ed) Stimulants: neurochemical, behavioral and clinical perspectives. Raven Press, New York, pp 301–339Google Scholar
  333. Robbins TW, Cador M, Taylor JR, Everitt BJ (1989) Limbic-striatal interactions in reward-related processes. Neurosci Biobehav Rev 13:155–162PubMedGoogle Scholar
  334. Robertson GS, Fibiger HC (1992) Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 46:315–328PubMedGoogle Scholar
  335. Robinson GB, Port RL, Stillwell EG (1993) Latent inhibition of the classically conditioned rabbit nictitating membrane response is unaffected by the NMDA antagonist MK-801. Psychobiology 21:120–124Google Scholar
  336. Robinson TE, Becker GB (1986) Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res Rev 11:157–198Google Scholar
  337. Rochford J, Sen AP, Quirion R (1996a) Effect of nicotine and nicotinic receptor agonists on latent inhibition in the rat. J Pharmacol Exp Ther 277:1267–1275PubMedGoogle Scholar
  338. Rochford J, Sen AP, Rousse I, Welner SA (1996b) The effect of quisqualic acid-induced lesions of the nucleus basalis magnocellularis on latent inhibition. Brain Res Bull 41:313–317CrossRefPubMedGoogle Scholar
  339. Romano AG (1999) Variations in CS associability and multiple unit hippocampal activity in the rabbit. Behav Brain Res 103:163–173CrossRefPubMedGoogle Scholar
  340. Rommelspacher H, Strauss S (1980) Effect of lesions of raphe nuclei on the activity of catecholaminergic and serotonergic neurones in various brain regions of the rat in vivo. J Neural Transm 49:51–62PubMedGoogle Scholar
  341. Rueter LE, Jacobs BL (1996) A microdialysis examination of serotonin release in the rat forebrain induced by behavioral/environmental manipulations. Brain Res 739:57–69PubMedGoogle Scholar
  342. Ruob C, Elsner J, Weiner I, Feldon J (1997) Amphetamine-induced disruption and haloperidol-induced potentiation of latent inhibition depend on the nature of the stimulus. Behav Brain Res 88:35–41CrossRefPubMedGoogle Scholar
  343. Ruob C, Weiner I, Feldon J (1998) Haloperidol-induced potentiation of latent inhibition: Interaction with parameters of conditioning. Behav Pharmacol 9:245–253PubMedGoogle Scholar
  344. Russig H, Murphy CA, Feldon J (2002) Clozapine and haloperidol reinstate latent inhibition following its disruption during amphetamine withdrawal. Neuropsychopharmacology 26:765–777CrossRefPubMedGoogle Scholar
  345. Salafia W, Allan AM (1980) Attenuation of latent inhibition by electrical stimulation of hippoampus. Physiol Behav 24:1047–1051PubMedGoogle Scholar
  346. Salafia W, Allan AM (1982) Augmentation of latent inhibition by electrical stimulation of hippoampus. Physiol Behav 29:1125–1230PubMedGoogle Scholar
  347. Salgado JV, Hetem LA, Vidal M, Graeff FG, Danion JM, Sandner G (2000) Reduction of latent inhibition by d-amphetamine in a conditioned suppression paradigm in humans. Behav Brain Res 117:61–77CrossRefPubMedGoogle Scholar
  348. Sams-Dodd F (1996) Phencyclidine-induced stereotyped behaviour and social isolation in rats: a possible animal model of schizophrenia. Behav Pharmacol 7:3–23PubMedGoogle Scholar
  349. Sams-Dodd F (1997) Effect of novel antipsychotic drugs on phencyclidine-induced stereotyped behaviour and social isolation in the rat social interaction test. Behav Pharmacol 8:196–215PubMedGoogle Scholar
  350. Sanfilipo M, Wolkin A, Angrist B, van Kammen DP, Duncan E, Wieland S, Cooper TB, Peselow ED, Rotrosen J (1996) Amphetamine and negative symptoms of schizophrenia. Psychopharmacology 123:211–214PubMedGoogle Scholar
  351. Sasaki-Adams DM, Kelley AE (2001) Serotonin-dopamine interactions in the control of conditioned reinforcement and motor behavior. Neuropsychopharmacology 25:441–452CrossRefGoogle Scholar
  352. Schauz C, Koch M (2000) Blockade of NMDA receptors in the amygdala prevents latent inhibition of fear-conditioning. Learn Mem 7:393–399CrossRefPubMedGoogle Scholar
  353. Schmajuk NA, Moore JW (1985) Real-time attentional models for classical conditioning and the hippocampus. Physiol Psychol 13:278–290Google Scholar
  354. Schmajuk NA, Moore JW (1988) The hippocampus and the classically conditioned nictitating membrane response: a real-time attentional-associative model. Psychobiology 16:20–35Google Scholar
  355. Schmajuk N, Lam YW, Christiansen BA (1994) Latent inhibition of the rat eyeblink response: effect of hippocampal aspiration lesions. Physiol Behav 55:597–601PubMedGoogle Scholar
  356. Schmajuk NA, Gray JA, Lam YW (1996) Latent inhibition: a neural network approach. J Exp Psychol Anim Behav Proc 22:321–349CrossRefGoogle Scholar
  357. Schmajuk NA, Buhusi CV, Gray JA (1998) Psychopharmacology of latent inhibition: a neural network approach. Behav Pharmacol 9:711–730PubMedGoogle Scholar
  358. Schmajuk NA, Cox L, Gray JA (2001) Nucleus accumbens, entorhinal cortex and latent inhibition: a neural network model. Behav Brain Res 118:123–141CrossRefPubMedGoogle Scholar
  359. Schotte A, Janssen PFM, Gommeren W, Luyten WHML, Van Gompel P, Lesage AS, De Loore K, Leysen JE (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124:57–73PubMedGoogle Scholar
  360. Schroeder U, Schroeder H, Darius J, Grecksch G, Sabel BA (1998) Simulation of psychosis by continuous delivery of PCP from controlled-release polymer implants. Behav Brain Res 97:59–68PubMedGoogle Scholar
  361. Schultz W (1998) Predictive reward signal of dopamine neurons. J Neurophysiol 80:1–27PubMedGoogle Scholar
  362. Segal M (1982) The action of serotonin in the rat hippocampus. In: Kohsaka M, T Shohmori, Y Tsukada, GN Woordruff (eds) Advances in dopamine research. Pergamon Press, New York, pp 375–389Google Scholar
  363. Serra AM, Jones SH, Toone B, Gray JA (2001) Impaired associative learning in chronic schizophrenics and their first- degree relatives: a study of latent inhibition and the Kamin blocking effect. Schizophr Res 48:273–289CrossRefPubMedGoogle Scholar
  364. Shadach E, Feldon J, Weiner I (1999) Clozapine-induced potentiation of latent inhibition is due to its action in the conditioning stage: implications for the mechanism of action of antipsychotic drugs. Int J Neuropsychopharmacol 2:283–291Google Scholar
  365. Shadach E, Gaisler I, Schiller D, Weiner I (2000) The latent inhibition model dissociates between clozapine, haloperidol, and ritanserin. Neuropsychopharmacology 23:151–161PubMedGoogle Scholar
  366. Shakow D (1962) Segmental set: a theory of the formal psychological deficit in schizophrenia. Arch Gen Psychiatry 6:17–33Google Scholar
  367. Shalev U, Feldon J, Weiner I (1998) Gender- and age-dependent differences in latent inhibition following pre-weaning non-handling: implications for a neurodevelopmental animal model of schizophrenia. Int J Dev Neurosci 16:279–788CrossRefPubMedGoogle Scholar
  368. Shohamy D, Allen MT, Gluck MA (2000) Dissociating entorhinal and hippocampal involvement in latent inhibition. Behav Neurosci 114:867–874CrossRefPubMedGoogle Scholar
  369. Sirvio J, Riekkinen P Jr, Jakala P, Riekkinen PJ (1994) Experimental studies on the role of serotonin in cognition. Prog Neurobiol 43:363–379PubMedGoogle Scholar
  370. Smith-Roe SL, Kelley AE (2000) Coincident activation of NMDA and dopamine D1 receptors within the nucleus accumbens core is required for appetitive instrumental learning. J Neurosci 20:7737–7742PubMedGoogle Scholar
  371. Snell JC, Chernyshev O, Gilbert DL, Colton CA (1997) Polyribonucleotides induce nitric oxide production by human monocyte-derived macrophages. J Leukoc Biol 62:369–373PubMedGoogle Scholar
  372. Snyder SH (1973) Amphetamine psychosis: a "model" schizophrenia mediated by catecholamines. Am J Psychiatry 130:61–67PubMedGoogle Scholar
  373. Snyder SH (1976) The dopamine hypothesis of schizophrenia: focus on the dopamine receptor. Am J Psychiatry 133:197–202PubMedGoogle Scholar
  374. Solomon P, Moore JW (1975) Latent inhibition and stimulus generalization of the classically conditioned nictitating membrane response in rabbits (Oryctolagus cuniculus) following dorsal hippocampal ablation. J Comp Physiol Psychol 89:1192–1203PubMedGoogle Scholar
  375. Solomon P, Staton DM (1982) Differential effects of microinjections of d-amphetamine into the nucleus accumbens or the caudate putamen on the rat's ability to ignore an irrelevant stimulus. Biol Psychiatry 17:743–756PubMedGoogle Scholar
  376. Solomon P, Kiney CA, Scott DR (1978) Disruption of latent inhibition following systemic administration of parachlorophenylalanine (PCPA). Physiol Behav 20:265–271Google Scholar
  377. Solomon P, Nichols GL, Kiernan JMI, Kamer RS, Kaplan LJ (1980) Differential effects of lesions in medial and dorsal raphe of the rat: latent inhibition and septo-hippocampal serotonin levels. J Comp Physiol Psychol 94:145–154PubMedGoogle Scholar
  378. Solomon P, Crider A, Winkelman JW, Turi A, Kamer RM, Kaplan LJ (1981) Disrupted latent inhibition in the rat with chronic amphetamine or haloperidol-induced supersensitivity: relationship to schizophrenic attention disorder. Biol Psychiatry 16:519–537PubMedGoogle Scholar
  379. Sotty F, Sandner G, Gosselin O (1996) Latent inhibition in conditioned emotional response: c-fos immunolabelling evidence for brain areas involved in the rat. Brain Res 737:243–254CrossRefPubMedGoogle Scholar
  380. Soubrie P (1986) Reconciling the role of central serotonin neurons in human and animal behavior. Behav Brain Sci 9:319–365Google Scholar
  381. Spitzer M, Braun U, Hermle L, Maier S (1993) Associative semantic network dysfunction in thought-disordered schizophrenic patients—direct evidence from indirect semantic priming. Biol Psychiatry 34:864–877PubMedGoogle Scholar
  382. Spoont MR (1992) Modulatory role of serotonin in neural information processing: Implications for human psychopathology. Psychol Bull 112:330–350PubMedGoogle Scholar
  383. Stahl SM (1988) Basal ganglia neuropharmacology and obsessive-compulsive disorder: the obsessive-compulsive disorder hypothesis of basal ganglia dysfunction. Psychopharmacol Bull 24:370–374PubMedGoogle Scholar
  384. Surmeier DJ, Calabresi P (2002) Cellular actions of dopamine. In: Di Chiara G (ed) Handbook of experimental pharmacology, vol 154/ii, dopamine in the CNS II. Springer, Berlin, pp 418–472Google Scholar
  385. Svensson TH (2000) Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drugs. Brain Res Rev 31:320–330PubMedGoogle Scholar
  386. Swanson CJ, Heath S, Stratford TR, Kelley AE (1997) Differential behavioral responses to dopaminergic stimulation of nucleus accumbens subregions in the rat. Pharmacol Biochem Behav 58:933–945PubMedGoogle Scholar
  387. Swerdlow NR, Koob GF (1987) Dopamine, schizophrenia, mania and depression: toward a unified hypothesis of cortico-striato-pallido-thalamic function. Behav Brain Sci 10:215–217Google Scholar
  388. Swerdlow NR, Bakshi V, Geyer MA (1996a) Seroquel restores sensorimotor gating in phencyclidine-treated rats. J Pharmacol Exp Ther 279:1290–1299PubMedGoogle Scholar
  389. Swerdlow NR, Braff DL, Hartston H, Perry W, Geyer MA (1996b) Latent inhibition in schizophrenia. Schizophr Res 20:91–103PubMedGoogle Scholar
  390. Taghzouti K, Louilot A, Herman J, Le Moal M, Simon H (1985a) Alternation behavior, spatial discrimination, and reversal disturbances following 6-hydroxydopamine lesions in the nucleus accumbens of the rat. Behav Neural Biol 44:354–363Google Scholar
  391. Taghzouti K, Simon H, Louilot A, Herman JP, Le Moal M (1985b) Behavioral study after local injection of 6-hydroxydopamine into the nucleus accumbens in the rat. Brain Res 345:9–20Google Scholar
  392. Tai CT, Cassaday HJ, Feldon J, Rawlins JNP (1995) Both electrolytic and excitotoxic lesions of nucleus accumbens disrupt latent inhibition of learning in rats. Neurobiol Learn Mem 64:36–48CrossRefPubMedGoogle Scholar
  393. Talamini LM, Koch T, Ter Horst GJ, Korf J (1998) Methylazoxymethanol acetate-induced abnormalities in the entorhinal cortex of the rat; parallels with morphological findings in schizophrenia. Brain Res 789:293–306PubMedGoogle Scholar
  394. Tamminga C (1998) Schizophrenia and glutamatergic transmission. Crit Rev Neurobiol 12:21–36Google Scholar
  395. Tamminga C (1999) Glutamatergic aspects of schizophrenia. Br J Psychiatry 174:12–15Google Scholar
  396. Tang AH, Ho PM (1988) Both competitive and non-competitive antagonists of N-methyl-d-aspartic acid disrupt brightness discrimination in rats. Eur J Pharmacol 151:143–146CrossRefPubMedGoogle Scholar
  397. Thornton JC, Dawe S, Lee C, Capstick C, Corr PJ, Cotter P, Frangou S, Gray NS, Russell MA, Gray JA (1996) Effects of nicotine and amphetamine on latent inhibition in human subjects. Psychopharmacology 127:164–173PubMedGoogle Scholar
  398. Tohyama Y, Yamane F, Merid MF, Diksic M (2001) Effects of selective 5-HT1A receptor antagonists on regional serotonin synthesis in the rat brain: an autoradiographic study with alpha-[14C]methyl-l-tryptophan. Eur Neuropsychopharmacol 11:193–202CrossRefPubMedGoogle Scholar
  399. Torrey EF (1991) A viral-anatomical explanation of schizophrenia. Schizophr Bull 17:15–18PubMedGoogle Scholar
  400. Totterdell S, Meredith GE (1997) Topographical organization of projections from the entorhinal cortex to the striatum of the rat. Neuroscience 78:715–729Google Scholar
  401. Trimble KM, Bell R, King DJ (1997) Enhancement of latent inhibition in the rat by the atypical antipsychotic agent remoxipride. Pharmacol Biochem Behav 56:809–816PubMedGoogle Scholar
  402. Trimble KM, Bell R, King DJ (1998) Enhancement of latent inhibition in the rat at a high dose of clozapine. J Psychopharmacol 12:215–219PubMedGoogle Scholar
  403. Trimble KM, Bell R, King DJ (2002) Effects of the selective dopamine D1 antagonists NNC 01–0112 and SCH 39166 on latent inhibition in the rat. Physiol Behav 77:115–123CrossRefPubMedGoogle Scholar
  404. Turgeon SM, Auerbach EA, Heller MA (1998) The delayed effects of phencyclidine (PCP) disrupt latent inhibition in a conditioned taste aversion paradigm. Pharmacol Biochem Behav 60:553–558CrossRefPubMedGoogle Scholar
  405. Turgeon SM, Auerbach EA, Duncan-Smith MK, George JR, Graves WW (2000) The delayed effects of DTG and MK-801 on latent inhibition in a conditioned taste-aversion paradigm. Pharmacol Biochem Behav 66:533–539CrossRefPubMedGoogle Scholar
  406. Tye NC, Everitt BJ, Iversen SD (1977) 5-Hydroxytryptamine and punishment. Nature 268:741–743PubMedGoogle Scholar
  407. Tzschentke TM (2001) Pharmacology and behavioral pharmacology of the mesocortical dopamine system. Prog Neurobiol 63:241–320Google Scholar
  408. Uchimura N, Higashi H, Nishi S (1986) Hyperpolarizing and depolarizing actions of dopamine via D-1 and D-2 receptors on nucleus accumbens neurons. Brain Res 375: 368–372PubMedGoogle Scholar
  409. Uphouse L (1997) Multiple serotonin receptors: too many, not enough, or just the right number? Neurosci Biobehav Rev 21:679–698Google Scholar
  410. Vaid RR, Yee BK, Shalev U, Rawlins JN, Weiner I, Feldon J, Totterdell S (1997) Neonatal nonhandling and in utero prenatal stress reduce the density of NADPH-diaphorase-reactive neurons in the fascia dentata and Ammon's horn of rats. J Neurosci 17:5599–5609PubMedGoogle Scholar
  411. Vaitl D, Lipp OV (1997) Latent inhibition and autonomic responses: a psychophysiological approach. Behav Brain Res 88:85–93Google Scholar
  412. Vaitl D, Lipp O, Bauer U, Schuler G, Stark R, Zimmermann M, Kirsch P (2002) Latent inhibition and schizophrenia: Pavlovian conditioning of autonomic responses. Schizophr Res 55:147–158CrossRefPubMedGoogle Scholar
  413. Van den Bos R, Cools AR (1989) The involvement of the nucleus accumbens in the ability of rats to switch to cue-directed behaviors. Life Sci 44:1697–1704PubMedGoogle Scholar
  414. Van Kammen DP, Docherty JP, Bunney WE Jr (1982) Prediction of early relapse after pimozide discontinuation by response to d-amphetamine during pimozide treatment. Biol Psychiatry 17:233–242PubMedGoogle Scholar
  415. Venables PH (1984) Cerebral mechanisms, autonomic responsiveness and attention in schizophrenia. In: Spaulding WD, JK Cole (eds) Theories of schizophrenia and psychosis. University of Nebraska Press, Lincoln, pp 47–91Google Scholar
  416. Vertes RP, Fortin WJ, Crane AM (1999) Projections of the median raphe nucleus in the rat. J Comp Neurol 408:555–582CrossRefGoogle Scholar
  417. Wagner AR, Rescorla RA (1972) Inhibition in Pavlovian conditioning: Application of a theory. In: Boakes RA, Halliday MA (eds) Inhibition and Learning. Academic Press, New YorkGoogle Scholar
  418. Warburton EC, Joseph MH, Feldon J, Weiner I, Gray JA (1994) Antagonism of amphetamine-induced disruption of latent inhibition in rats by haloperidol and ondansetron—implications for a possible antipsychotic action of ondansetron. Psychopharmacology 114:657–664PubMedGoogle Scholar
  419. Warburton EC, Mitchell SN, Joseph MH (1996) Calcium dependence of sensitised dopamine release in rat nucleus accumbens following amphetamine challenge: implications for the disruption of latent inhibition. Behav Pharmacol 7:119–129PubMedGoogle Scholar
  420. Weinberger DR (1987) Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 44:660–669PubMedGoogle Scholar
  421. Weinberger DR (1995) From neuropathology to neurodevelopment. Lancet 347:552–557Google Scholar
  422. Weinberger DR, Lipska BK (1995) Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground. Schizophr Res 16:87–110PubMedGoogle Scholar
  423. Weiner I (1990) Neural substrates of latent inhibition: The switching model. Psychol Bull 108:443–461Google Scholar
  424. Weiner I (2000) The latent inhibition model of schizophrenia. In: Myslobodsky MS, Weiner I (eds) Contemporary issues in modeling psychopathology. Kluwer, pp 197–230Google Scholar
  425. Weiner I (2001) Latent inhibition. In: Crawley JN, Gerfen CR, Rogawski MA, Sibley DR, Skolnick P (eds) Current protocols in neuroscience. Wiley, New YorkGoogle Scholar
  426. Weiner I, Feldon J (1987) Facilitation of latent inhibition by haloperidol in rats. Psychopharmacology 91:248–253PubMedGoogle Scholar
  427. Weiner I, Feldon J (1992) Phencyclidine does not disrupt latent inhibition in rats: implications for animal models of schizophrenia. Pharmacol Biochem Behav 42:625–631CrossRefPubMedGoogle Scholar
  428. Weiner I, Feldon J (1997) The switching model of latent inhibition: An update of neural substrates. Behav Brain Res 88:11–25PubMedGoogle Scholar
  429. Weiner I, Joel D (2002) Dopamine in schizophrenia: Dysfunctional information processing in basal ganglia-thalamocortical split circuits. In: Di Chiara G (ed) Handbook of Experimental Pharmacology, vol 154/II, Dopamine in the CNS II. Springer, Berlin, pp 418–472Google Scholar
  430. Weiner I, Lubow RE, Feldon J (1981) Chronic amphetamine and latent inhibition. Behav Brain Res 2:285–286Google Scholar
  431. Weiner I, Lubow RE, Feldon J (1984) Abolition of the expression but not the acquisition of latent inhibition by chronic amphetamine in rats. Psychopharmacology 83:194–199Google Scholar
  432. Weiner I, Schnabel I, Lubow RE, Feldon J (1985) The effects of early handling on latent inhibition in male and female rats. Dev Psychobiol 18:291–297PubMedGoogle Scholar
  433. Weiner I, Feldon J, Katz Y (1987a) Facilitation of the expression but not the acquisition of latent inhibition by haloperidol in rats. Pharmacol Biochem Behav 26:241–246PubMedGoogle Scholar
  434. Weiner I, Feldon J, Ziv-Harris D (1987b) Early handling and latent inhibition in the conditioned suppression paradigm. Dev Psychobiol 20:233–240Google Scholar
  435. Weiner I, Izraeli-Telerant A, Feldon J (1987c) Latent inhibition is not affected by acute or chronic administration of 6 mg/kg dl-amphetamine. Psychopharmacology 91:346–352Google Scholar
  436. Weiner I, Lubow RE, Feldon J (1988) Disruption of latent inhibition by acute administration of low doses of amphetamine. Pharmacol Biochem Behav 30:871–878PubMedGoogle Scholar
  437. Weiner I, Smith AD, Rawlins JN, Feldon J (1992) A neuroleptic-like effect of ceronapril on latent inhibition. Neuroscience 49:307–315PubMedGoogle Scholar
  438. Weiner I, Kidron R, Tarrasch R, Arnt J, Feldon J (1994) The effects of the new antipsychotic, sertindole, on latent inhibition in rats. Behav Pharmacol 5:119–124PubMedGoogle Scholar
  439. Weiner I, Traub A, Rawlins JNP, Smith AD, Feldon J (1995) The sigma ligand BMY-14802 as a potential antipsychotic: Evidence from the latent inhibition model in rats. Behav Pharmacol 6:46–54PubMedGoogle Scholar
  440. Weiner I, Gal G, Rawlins JN, Feldon J (1996a) Differential involvement of the shell and core subterritories of the nucleus accumbens in latent inhibition and amphetamine-induced activity. Behav Brain Res 81:123–133CrossRefPubMedGoogle Scholar
  441. Weiner I, Shadach E, Tarrasch R, Kidron R, Feldon J (1996b) The latent inhibition model of schizophrenia: further validation using the atypical neuroleptic, clozapine. Biol Psychiatry 1996:834–843CrossRefGoogle Scholar
  442. Weiner I, Tarrasch R, Feldon J (1996c) Basolateral amygdala lesions do not disrupt latent inhibition. Behav Brain Res 72:73–81CrossRefGoogle Scholar
  443. Weiner I, Bernasconi E, Broersen LM, Feldon J (1997a) Amphetamine-induced disruption of latent inhibition depends on the nature of the stimulus. Behav Pharmacol 8:443–457Google Scholar
  444. Weiner I, Shadach E, Barkai R, Feldon J (1997b) Haloperidol- and clozapine-induced enhancement of latent inhibition with extended conditioning: Implications for the mechanism of action of neuroleptic drugs. Neuropsychopharmacology 16:42–50CrossRefPubMedGoogle Scholar
  445. Weiner I, Tarrasch R, Bernasconi E, Broersen LM, Ruttimann TC, Feldon J (1997c) Amphetamine-induced disruption of latent inhibition is not reinforcer- mediated. Pharmacol Biochem Behav 56:817–826CrossRefPubMedGoogle Scholar
  446. Weiner I, Feldon J, Tarrasch R, Hairston I, Joel D (1998) Fimbria-fornix cut affects spontaneous activity, two-way avoidance and delayed non matching to sample, but not latent inhibition. Behav Brain Res 96:59–70PubMedGoogle Scholar
  447. Weiner I, Gal G, Feldon J (1999) Disrupted and undisruptable latent inhibition following shell and core lesions. Ann NY Acad Sci 877:723–727PubMedGoogle Scholar
  448. Weiner I, Gaisler I, Schiller D, Green A, Zuckerman L, Joel D (2000) Screening of antipsychotic drugs in animal models. Drug Dev Res 50:235–249CrossRefGoogle Scholar
  449. Weiner I, Schiller D, Gaisler-Salomon I (2003) Disruption and potentiation of latent inhibition by risperidone: the latent inhibition model of atypical antipsychotic action. Neuropsychopharmacology (in press)Google Scholar
  450. Weiss IC, Domeney AM, Moreau JL, Russig H, Feldon J (2001) Dissociation between the effects of pre-weaning and/or post-weaning social isolation on prepulse inhibition and latent inhibition in adult Sprague-Dawley rats. Behav Brain Res 121:207–218PubMedGoogle Scholar
  451. Wellner SA, Rousse I, Rochford J (1995) Transplants to the cerebral cortex of nucleus basalis magnocellularis- lesioned rats: effects on deficits in latent inhibition. Brain Res 671:309–313CrossRefPubMedGoogle Scholar
  452. Westerink BHC, Kwint HF, de Vries JB (1997) Eating-induced dopamine release from mesolimbic neurons is mediated by NMDA receptors in the ventral tegmental area: a dual probe microdialysis study. J Neurochem 69:662–668PubMedGoogle Scholar
  453. Wilkinson LS, Killcross SS, Humby T, Hall FS, Geyer MA, Robbins TW (1994) Social isolation in the rat produces developmentally specific deficits in prepulse inhibition of the acoustic startle response without disrupting latent inhibition. Neuropsychopharmacology 10:61–72Google Scholar
  454. Williams JH, Azmitia EC (1981) Hippocampal serotonin re-uptake and nocturnal locomotor activity after microinjections of 5,7-DHT in the fornix-fimbria. Brain Res 207:95–107PubMedGoogle Scholar
  455. Williams JH, Wellman NA, Geaney DP, Cowen PJ, Feldon J, Rawlins JN (1996) Antipsychotic drug effects in a model of schizophrenic attentional disorder: a randomized controlled trial of the effects of haloperidol on latent inhibition in healthy people. Biol Psychiatry 40:1135–1143PubMedGoogle Scholar
  456. Williams JH, Wellman NA, Geaney DP, Feldon J, Cowen PJ, Rawlins JNP (1997) Haloperidol enhances latent inhibition in visual tasks in healthy people. Psychopharmacology 133:262–268PubMedGoogle Scholar
  457. Williams JH, Wellman NA, Geaney DP, Cowen PJ, Feldon J, Rawlins JN (1998) Reduced latent inhibition in people with schizophrenia: an effect of psychosis or of its treatment. Br J Psychiatry 172:243–249PubMedGoogle Scholar
  458. Winson J, Abzug C (1977) Gating of neuronal transmission in the hippocampus: efficacy of transmission varies with behavioral state. Science 196:1223–1225PubMedGoogle Scholar
  459. Wolf ME (1998) The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants. Prog Neurobiol 54:679–720PubMedGoogle Scholar
  460. Wolkin A, Sanfilipo M, Wolf AP, Angrist B, Brodie JD, Rotrosen J (1992) Negative symptoms and hypofrontality in chronic schizophrenia. Arch Gen Psychiatry 49:959–965PubMedGoogle Scholar
  461. Wright IK, Garratt JC, Marsden CA (1990) Effects of a selective 5-HT2 agonist, DOI, on 5-HT neuronal firing in the dorsal raphe nucleus and 5-HT release and metabolism in the frontal cortex. Br J Pharmacol 99:221–222PubMedGoogle Scholar
  462. Wu YN, Shen KZ, Johnson SW (1999) Presynaptic inhibition preferentially reduces NMDA receptor-mediated component of transmission in rat midbrain dopamine neurons. Br J Pharmacol 127:1423–1431Google Scholar
  463. Wuthrich V, Bates TC (2001) Schizotypy and latent inhibition: non-linear linkage between psychometric and cognitive markers. Person Indiv Diff 30:783–798CrossRefGoogle Scholar
  464. Yan QS, Reith ME, Jobe PC, Dailey JW (1997) Dizocilpine (MK-801) increases not only dopamine but also serotonin and norepinephrine transmissions in the nucleus accumbens as measured by microdialysis in freely moving rats. Brain Res 765:149–158CrossRefPubMedGoogle Scholar
  465. Yan Z, Song WJ, Surmeier J (1997) D2 dopamine receptors reduce N-type Ca2+ currents in rat neostriatal cholinergic interneurons through a membrane-delimited, protein-kinase-C- insensitive pathway. J Neurophysiol 77:1003–1015PubMedGoogle Scholar
  466. Yee BK, Feldon J, Rawlins JNP (1995) Latent inhibition in rats is abolished by NMDA-induced neuronal loss in the retrohippocampal region but this lesion effect can be prevented by systemic haloperidol treatment. Behav Neurosci 109:227–240PubMedGoogle Scholar
  467. Yee BK, Feldon J, Rawlins JN (1997) Cytotoxic lesions of the retrohippocampal region attenuate latent inhibition but spare the partial reinforcement extinction effect. Exp Brain Res 115:247–256PubMedGoogle Scholar
  468. Young AMJ, Joseph MH, Gray JA (1993) Latent inhibition of conditioned dopamine release in rat nucleus accumbens. Neuroscience 54:5–9PubMedGoogle Scholar
  469. Zahm DS (1999) Functional-anatomical implications of the nucleus accumbens core and shell subterritories. Ann NY Acad Sci 877:113–128PubMedGoogle Scholar
  470. Zahm DS (2000) An integrative neuroanatomical perspective on some subcortical substrates of adaptive responding with emphasis on the nucleus accumbens. Neurosci Biobehav Rev 24:85–105PubMedGoogle Scholar
  471. Zahm DS, Brog JS (1992) On the significance of subterritories in the "accumbens" part of the rat ventral striatum. Neuroscience 50:751–767PubMedGoogle Scholar
  472. Zhang J, Chiodo LA, Freeman AS (1992) Electrophysiological effects of MK-801 on rat nigrostriatal and mesoaccumbal dopaminergic neurons. Brain Res 590:153–163PubMedGoogle Scholar
  473. Zhang WN, Bast T, Feldon J (2000) Microinfusion of the non-competitive N-methyl-d-aspartate receptor antagonist MK-801 (dizocilpine) into the dorsal hippocampus of wistar rats does not affect latent inhibition and prepulse inhibition, but increases startle reaction and locomotor activity. Neuroscience 101:589–599Google Scholar
  474. Zuckerman L, Ben-Eliyahu S, Weiner I (2001a) Maternal immune stimulation leads to cognitive deficits in the adult offspring which are alleviated by antipsychotic treatment: a novel neurodevelopmental model of schizophrenia in the rat. Eur Neuropsychopharmacol 11:246Google Scholar
  475. Zuckerman L, Joel D, Weiner I (2001b) Nucleus accumbens core lesion produces persistent latent inhibition which is reversed by clozapine but not haloperidol. World J Biol Psychiatry 2:S36Google Scholar
  476. Zuckerman L, Rehavi M, Nachman R, Weiner I (2001c) Immune activation during pregnancy leads to a post-pubertal emergence of an attentional deficit and a dopaminergic hyperfunction in the offspring: a novel neurodevelopmental model of schizophrenia. Neural Plasticity 8:210Google Scholar
  477. Zuckerman L, Grace AA, Weiner I, Moore H (2002) Prenatal administration of methylazoxymethanol leads to a post-pubertal emergence of a latent inhibition deficit accompanied by altered morphology in limbic and paralimbic cortical structures in the offspring. FENS Abstr 1:168.3Google Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  1. 1.Department of PsychologyTel-Aviv UniversityTel-AvivIsrael

Personalised recommendations